Resolver scheme
Router Condition:
is_page_template()
Controller:
/Controllers/PressController.php
Method:
archiveAction()
View:
views/cpt/press-releases/archive.twig
- Request resolved at functions.php which launches the AppKernel.
- AppKernel registers all Managers and the App\Managers\RoutingManager.
- The Router resolve the template condition is_page_template().
- The Router retrieves the routing configuration in the template declaration file App/config/templates.yml
- The Router calls PressController() archiveAction() which renders the template views/cpt/press-releases/archive.twig
PressController
Controller
| path | /Controllers/PressController.php |
| abs_path | /bitnami/wordpress/wp-content/themes/yagami-adveris/Controllers/PressController.php |
Render
| view | views/cpt/press-releases/archive.twig |
Datas
^ array:2 [ "post" => Timber\Post {#2554 +id: 419 +ID: 419 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:11 [ "_edit_last" => "1" "_wp_page_template" => "press" "_yoast_wpseo_estimated-reading-time-minutes" => "0" "_yoast_wpseo_wordproof_timestamp" => "" "references" => "" "_references" => "field_644943738e91a" "_edit_lock" => "1692709771:4" "featured_pages" => array:1 [ 0 => "432" ] "_featured_pages" => "field_64522e2a4e468" "_yoast_wpseo_title" => "%%sitename%% %%sep%% %%title%%" "_yoast_wpseo_metadesc" => "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." ] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: "" +post_date: "2023-05-03 11:09:45" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "Press Release" +post_type: "page" +slug: "press-release" #__type: null +"_edit_last": "1" +"_wp_page_template": "press" +"_yoast_wpseo_estimated-reading-time-minutes": "0" +"_yoast_wpseo_wordproof_timestamp": "" +"references": "" +"_references": "field_644943738e91a" +"_edit_lock": "1692709771:4" +"featured_pages": array:1 [ 0 => "432" ] +"_featured_pages": "field_64522e2a4e468" +"_yoast_wpseo_title": "%%sitename%% %%sep%% %%title%%" +"_yoast_wpseo_metadesc": "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." +"post_date_gmt": "2023-05-03 09:09:45" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "press-release" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-27 16:52:08" +"post_modified_gmt": "2023-06-27 14:52:08" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?page_id=419" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } "posts" => Timber\PostQuery {#2553 +found_posts: 11 : 11 #userQuery: array:3 [ "post_type" => "press_releases" "posts_per_page" => 12 "paged" => 1 ] #queryIterator: Timber\QueryIterator {#2555 -_query: WP_Query {#2556 +query: array:3 [ "post_type" => "press_releases" "posts_per_page" => 12 "paged" => 1 ] +query_vars: array:65 [ "post_type" => "press_releases" "posts_per_page" => 12 "paged" => 1 "error" => "" "m" => "" "p" => 0 "post_parent" => "" "subpost" => "" "subpost_id" => "" "attachment" => "" "attachment_id" => 0 "name" => "" "pagename" => "" "page_id" => 0 "second" => "" "minute" => "" "hour" => "" "day" => 0 "monthnum" => 0 "year" => 0 "w" => 0 "category_name" => "" "tag" => "" "cat" => "" "tag_id" => "" "author" => "" "author_name" => "" "feed" => "" "tb" => "" "meta_key" => "" "meta_value" => "" "preview" => "" "s" => "" "sentence" => "" "title" => "" "fields" => "" "menu_order" => "" "embed" => "" "category__in" => [] "category__not_in" => [] "category__and" => [] "post__in" => [] "post__not_in" => [] "post_name__in" => [] "tag__in" => [] "tag__not_in" => [] "tag__and" => [] "tag_slug__in" => [] "tag_slug__and" => [] "post_parent__in" => [] "post_parent__not_in" => [] "author__in" => [] "author__not_in" => [] "search_columns" => [] "ignore_sticky_posts" => false "suppress_filters" => false "cache_results" => true "update_post_term_cache" => true "update_menu_item_cache" => false "lazy_load_term_meta" => true "update_post_meta_cache" => true "nopaging" => false "comments_per_page" => "50" "no_found_rows" => false "order" => "DESC" ] +tax_query: WP_Tax_Query {#2559 +queries: [] +relation: "AND" #table_aliases: [] +queried_terms: [] +primary_table: "wp_posts" +primary_id_column: "ID" } +meta_query: WP_Meta_Query {#2558 +queries: [] +relation: null +meta_table: null +meta_id_column: null +primary_table: null +primary_id_column: null #table_aliases: [] #clauses: [] #has_or_relation: false } +date_query: false +request: """ SELECT SQL_CALC_FOUND_ROWS wp_posts.ID\n \t\t\t\t\t FROM wp_posts \n \t\t\t\t\t WHERE 1=1 AND ((wp_posts.post_type = 'press_releases' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'acf-disabled')))\n \t\t\t\t\t \n \t\t\t\t\t ORDER BY wp_posts.post_date DESC\n \t\t\t\t\t LIMIT 0, 12 """ +posts: array:11 [ 0 => WP_Post {#2550 +ID: 1366 +post_author: "7" +post_date: "2024-09-19 17:37:57" +post_date_gmt: "2024-09-19 15:37:57" +post_content: "" +post_title: "Test" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "test" +to_ping: "" +pinged: "" +post_modified: "2024-10-07 14:19:21" +post_modified_gmt: "2024-10-07 12:19:21" +post_content_filtered: "" +post_parent: 0 +guid: "https://sgv.disko.love/?post_type=press_releases&p=1366" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 1366 +"slug": "test" +"custom": array:50 [ "_edit_lock" => "1728303459:7" "_edit_last" => "7" "content_0_text" => """ <h1>Block "Rich text"</h1>\r\n Content > Rich text\r\n \r\n b<strong>old </strong><em>italic </em><a href="#tata">link</a>\r\n <h1></h1> """ "_content_0_text" => "field_65785f61cbff7" "content" => array:5 [ 0 => "rich-text" 1 => "image" 2 => "image" 3 => "content-image" 4 => "content-image" ] "_content" => "field_65785f1ecbff6" "video_poster" => "1201" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "1368" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "1210" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "Block "Push (Link)"" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => array:3 [ "title" => "CTA" "url" => "https://sgv.disko.love/the-prevention-of-eye-disease-in-children-4-top-tips/" "target" => "" ] "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "custom" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "Mentions" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_estimated-reading-time-minutes" => "1" "content_1_image" => "1125" "_content_1_image" => "field_65785f7acbffa" "content_1_size" => "medium" "_content_1_size" => "field_65785f87cbffb" "content_3_image" => "1127" "_content_3_image" => "field_65785fe3cbffe" "content_3_text" => "Block "Content + Image" 50/50" "_content_3_text" => "field_65785ff8cc000" "content_3_disposition" => "equal" "_content_3_disposition" => "field_65786012cc001" "content_2_image" => "1125" "_content_2_image" => "field_65785f7acbffa" "content_2_size" => "small" "_content_2_size" => "field_65785f87cbffb" "related_news" => array:2 [ 0 => "1302" 1 => "1300" ] "_related_news" => "field_644bbb809ed4d" "_thumbnail_id" => "1127" "content_4_image" => "1127" "_content_4_image" => "field_65785fe3cbffe" "content_4_text" => "Block "Content + Image" 25/75" "_content_4_text" => "field_65785ff8cc000" "content_4_disposition" => "small" "_content_4_disposition" => "field_65786012cc001" ] } 1 => WP_Post {#2549 +ID: 1260 +post_author: "2" +post_date: "2023-10-09 13:53:53" +post_date_gmt: "2023-10-09 11:53:53" +post_content: """ <p style="text-align: center;"><em>CYPRESS 48-Month Efficacy Study, Prof Wolffsohn Visual Experience Study, and Dr. Ho Real-World Clinical Records Review Further Strengthen Evidence Base for DOT 0.2 Spectacle Lenses.</em></p>\r\n \r\n \r\n <strong>NEW ORLEANS, October 9, 2023</strong>—Findings from three <a href="http://sgv.disko.love/">SightGlass Vision</a> Diffusion Optics Technology<sup>™ </sup>(DOT 0.2) spectacle lenses studies will take center stage at the American Academy of Optometry 2023 Annual Meeting, which opens this week in New Orleans. Individually and collectively, they reinforce the robust performance of the company’s flagship myopia control intervention, which uses thousands of light scattering elements called dots to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.\r\n \r\n \r\n \r\n In-depth data from <a href="https://eppro02.ativ.me/web/index.php?page=Session&project=AAOPT23&id=P-03-03"><strong><em>Control of Myopia Using Diffusion Optics Technology Spectacle Lenses: 4-Year Results</em></strong><strong> <em>(CYPRESS)</em></strong></a> are being presented by Dr. Debbie Laughton on October 11, demonstrating statistically significant slowing of axial length (AL) progression and cycloplegic spherical equivalent refraction (cSER). Expanding on <a href="http://sgv.disko.love/releases/sightglass-vision-reports-positive-four-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/">top line findings shared last month</a> from the rigorous, multi-site study, researchers report that children wearing their DOT 0.2 spectacles full-time continue to show substantial clinical benefit over 48 months.\r\n \r\n \r\n \r\n Among the additional data reported at Academy ’23 is visual performance among CYPRESS participants over the four-year span. Mean binocular high contrast LogMAR visual acuity (VA) measurements were clinically stable and similar between groups at distance (test -0.09 ± 0.08, control -0.07 ± 0.06) and near (test -0.03 ± 0.14, control -0.04 ± 0.10). Mean monocular low contrast (10%) distance VA showed an improvement over the course of the study (mean change from baseline: test 0.05 ± 0.12, control 0.07 ± 0.11), and mean peripheral VA improved or remained similar in all quadrants, with no significant differences between treatment groups.\r\n \r\n \r\n \r\n The CYPRESS paper has been selected by the Academy as one of the six most newsworthy presentations scheduled for New Orleans. Dr. Laughton will summarize the work during the Academy-hosted Innovations in Vision and Eye Care event on Wednesday, October 11.\r\n \r\n \r\n \r\n A companion study co-developed by esteemed researcher and Professor James Wolffsohn of Aston University assessed the <a href="https://eppro02.ativ.me/web/index.php?page=Session&project=AAOPT23&id=Board-131"><strong><em>Visual Impact of Diffusion Optics Technology Lenses for Myopia Control</em></strong></a>. Children (12.2±1.3 years old, range 10-14, 51% female) were randomly assigned to wear DOT 0.2 spectacle lenses (n=27) or single vision lenses (n=24) for 3.5 years across six North American sites. Investigators determined that the DOT 0.2 lens provides an equivalent visual experience to a standard single vision lens, as evaluated through binocular high and low contrast distance visual acuities, near visual acuity, reading speed, contrast sensitivity, stereoacuity and glare measures.\r\n \r\n \r\n \r\n Presented by Dr. Kylvin Ho of C U Vision Optometrists (Vancouver), <a href="https://eppro02.ativ.me/web/index.php?page=Session&project=AAOPT23&id=Board-130"><strong><em>Real-World Effectiveness of Diffusion Optics Technology (DOT) Spectacle Lenses for Myopia Control in Chinese Canadian Children</em></strong></a> identified 39 patients who were prescribed the intervention as a monotherapy between October 2020 to December 2022 in an independent practice. After 12 months, mean progression was -0.28 ± 0.32 D in SER (n=39) and 0.15 ± 0.17 mm in AL (n=36). SER progression was limited to -0.25 D or less in 56% of children during the time frame.\r\n \r\n \r\n \r\n Compared to Singapore Cohort Study of the Risk Factors for Myopia (SCORM) data, DOT 0.2 lenses slowed AL progression by 62% (0.24 mm). The 12-month AL elongation was similar to 0.14 mm SCORM-predicted, age-matched emmetropic eye growth (physiological eye growth). The Canadian practice data also aligned with CYPRESS study 12-month outcomes of 0.15 mm AL progression.\r\n \r\n \r\n \r\n “Myopia progression is one of the greatest health epidemics of our time, deserving of attention and resources from researchers, educators, and policy makers. The evidence-based efficacy and impact of Diffusion Optics Technology<sup>™</sup> spectacle lenses, clearly and convincingly demonstrated across multiple dimensions at Academy ’23, shows their substantial potential to change the lives of children around the world. We thank the Academy for recognizing CYPRESS as among the most compelling and robust science to be presented this year, and we look forward to sharing more with colleagues over the coming days,” said Andrew Sedgwick, CEO of SightGlass Vision.\r\n \r\n \r\n \r\n Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy<a href="#_edn1" name="_ednref1">[i]</a><sup>,</sup><a href="#_edn2" name="_ednref2">[ii]</a><sup>,</sup><a href="#_edn3" name="_ednref3">[iii]</a> made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n \r\n \r\n For more information, visit <a href="http://sgv.disko.love">SightGlassVision.com</a>.\r\n \r\n <strong>About SightGlass Vision</strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n <em>SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.</em>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA, FAAO\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-545-1815 or mike@mcdougallpr.com\r\n \r\n \r\n \r\n <a href="#_ednref1" name="_edn1">[i]</a> Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n \r\n \r\n <a href="#_ednref2" name="_edn2">[ii]</a> Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n \r\n \r\n <a href="#_ednref3" name="_edn3">[iii]</a> Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022. """ +post_title: "SightGlass Vision Presents New Data at Academy ’23, Reinforcing Diffusion Optics Technology™ Myopia Control Impact" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-presents-new-data-at-academy-23-reinforcing-diffusion-optics-technology-myopia-control-impact" +to_ping: "" +pinged: "" +post_modified: "2023-10-24 10:55:21" +post_modified_gmt: "2023-10-24 08:55:21" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=1260" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 1260 +"slug": "sightglass-vision-presents-new-data-at-academy-23-reinforcing-diffusion-optics-technology-myopia-control-impact" +"custom": array:26 [ "_edit_lock" => "1726843767:7" "_edit_last" => "1" "_thumbnail_id" => "1261" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "5" "_yoast_wpseo_wordproof_timestamp" => "" ] } 2 => WP_Post {#2548 +ID: 1253 +post_author: "2" +post_date: "2023-09-20 14:54:01" +post_date_gmt: "2023-09-20 12:54:01" +post_content: """ <strong>LOS ALTOS, CALIF., September 20, 2023</strong>—<a href="http://sgv.disko.love/">SightGlass Vision</a> today announced the release of its <a href="http://sgv.disko.love/resources-for-eye-care-professionals/">first white paper</a> regarding the company’s Diffusion Optics Technology<sup>™ </sup>(DOT 0.2) spectacle lenses. The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.\r\n \r\n \r\n \r\n The in-depth paper explains the relationship between artificially high contrast signals at the retina and myopia progression. This groundbreaking research led to the development of DOT to manage such contrast, now clinically proven via the pivotal CYPRESS study to slow myopia progression in children from age six. Its efficacy is particularly of note for the youngest patients, who would typically experience the fastest progression.\r\n \r\n \r\n \r\n The white paper can be read online or downloaded as a PDF at <a href="http://sgv.disko.love/resources-for-eye-care-professionals/">http://sgv.disko.love/resources-for-eye-care-professionals/</a>\r\n \r\n \r\n \r\n “Harnessing the power of contrast management is a revolutionary approach to controlling myopia. Our DOT spectacle lenses are now paving a new path to reducing myopia progression from an early age. This white paper goes deeper into the science to explain the mechanisms of action, helping eye care professionals better understand the innovation,” said SightGlass Vision Vice President of Clinical, Medical & Professional Affairs Marcella McParland.\r\n \r\n \r\n \r\n “As a more recent entrant into the myopia management field, our Diffusion Optics Technology paper will help disseminate the substantial science behind contrast management and its application. DOT spectacle lenses present a compelling alternative to existing solutions for slowing myopia’s progression in children,” added Andrew Sedgwick, SightGlass Vision’s CEO.\r\n \r\n \r\n \r\n Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy<sup>1,2,3,4</sup> made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n \r\n \r\n For more information, visit <a href="http://sgv.disko.love">SightGlassVision.com</a>.\r\n \r\n \r\n <ol>\r\n \t<li>Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.</li>\r\n </ol>\r\n \r\n <ol start="2">\r\n \t<li>Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005</li>\r\n </ol>\r\n \r\n <ol start="3">\r\n \t<li>Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.</li>\r\n </ol>\r\n \r\n <ol start="4">\r\n \t<li>Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.</li>\r\n </ol>\r\n \r\n <h5>About SightGlass Vision</h5>\r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <em>SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.</em>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA, FAAO\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-545-1815 or mike@mcdougallpr.com """ +post_title: "SightGlass Vision Releases First White Paper on Diffusion Optics Technology™" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-releases-first-white-paper-on-diffusion-optics-technology" +to_ping: "" +pinged: "" +post_modified: "2023-10-24 11:07:09" +post_modified_gmt: "2023-10-24 09:07:09" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=1253" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 1253 +"slug": "sightglass-vision-releases-first-white-paper-on-diffusion-optics-technology" +"custom": array:26 [ "_edit_lock" => "1698138530:1" "_edit_last" => "1" "_thumbnail_id" => "1197" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "60" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" ] } 3 => WP_Post {#2547 +ID: 1228 +post_author: "2" +post_date: "2023-09-05 22:30:59" +post_date_gmt: "2023-09-05 20:30:59" +post_content: """ <p style="text-align: center;"><em>Compelling Axial Length and cSER Findings, Plus New Case Reviews from Chinese Children,\r\n Presented at the 27<sup>th</sup> Congress of the Chinese Ophthalmological Society</em></p>\r\n \r\n \r\n \r\n \r\n <strong>CHANGSHA, China, September 6, 2023</strong>—<a href="http://sgv.disko.love/">SightGlass Vision</a> today reported positive four-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology<sup>™ </sup>(DOT 0.2) spectacle lenses. The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.\r\n \r\n \r\n \r\n The findings are being presented at the 27th Congress of the Chinese Ophthalmological Society (CCOS), held in Changsha, Hunan Province. Thousands of eye care clinicians, researchers, and educators from across China and overseas attend the biennial event.\r\n \r\n \r\n \r\n <em>Control of Myopia using Diffusion Optics Technology Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 4 Year Results</em> (Zhu X, McParland M, et al) affirmed DOT 0.2 safety and efficacy in children aged 6–10 at the study’s initiation.<sup>¹</sup> Part two of the study—designed to collect 12 additional months of data—re-enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial.\r\n \r\n \r\n \r\n Full four-year outcomes showed statistically significant slowing of axial length progression and cycloplegic spherical equivalent refraction (cSER), with the most recent data underscoring strong DOT 0.2 performance. During the 36- to 48-month timeframe, axial length mean change was 0.13 ±0.02 mm for the test group (n=55) and 0.18 ±0.02 mm for the control (n=41; p=0.038). cSER mean change was -0.25 ±0.04 D for the test group and -0.38 ±0.05 D for control (p=0.043).\r\n \r\n \r\n \r\n “<em>The CYPRESS four-year findings confirm the demonstrated efficacy, safety, and overall performance of Diffusion Optics Technology™ spectacle lenses</em>,” said Andrew Sedgwick, CEO of SightGlass Vision. “<em>Eye care professionals worldwide are demanding this level of scientific rigor, allowing them to confidently recommend the lenses to children and their caregivers. SightGlass Vision is proud to advance the myopia control category with our latest research and technologies, and enthusiastic about growing opportunities for spectacles in a child’s treatment regimen.</em>”\r\n \r\n \r\n \r\n A separate presentation at CCOS explored the theoretical basis and practical application of DOT lenses. <em>Discussion of DOT Lenses Based on Contrast Reduction Theory and Real-World Case Sharing</em> (Wang D, Xie P, Huang J) analyzed the influence of contrast in children's refractive development, the interaction between contrast signals and peripheral defocus signals, and the clinical performance of DOT lenses based on contrast reduction. Comparing existing studies with clinical observations of 117 Chinese children wearing DOT 0.2 lenses for 1 year, investigators concluded that contrast management , and that the lenses were effective and safe.\r\n \r\n \r\n \r\n Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy<sup> ¹,²,³,⁴ </sup>made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n \r\n \r\n For more information, visit <a href="http://sgv.disko.love">SightGlassVision.com</a>.\r\n \r\n \r\n \r\n <strong>About SightGlass Vision</strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n <em>SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.</em>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA, FAAO\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-545-1815 or mike@mcdougallpr.com\r\n \r\n -------------------------------------------------\r\n \r\n <a href="#_ednref1" name="_edn1"></a>\r\n \r\n 1.Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 2. Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 3. Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 4. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n \r\n \r\n """ +post_title: "SightGlass Vision Reports Positive Four-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenses" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-reports-positive-four-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses" +to_ping: "" +pinged: "" +post_modified: "2023-10-24 11:04:42" +post_modified_gmt: "2023-10-24 09:04:42" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=1228" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 1228 +"slug": "sightglass-vision-reports-positive-four-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses" +"custom": array:26 [ "_edit_lock" => "1726760119:7" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "4" "_yoast_wpseo_wordproof_timestamp" => "" "_thumbnail_id" => "1229" ] } 4 => WP_Post {#2546 +ID: 770 +post_author: "1" +post_date: "2023-06-06 12:17:31" +post_date_gmt: "2023-06-06 10:17:31" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n <strong>LOS ALTOS, CALIF., June 6, 2023</strong>—With a goal to continuously improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference. Taking place from June 9-11 in Manchester, England, the event is expected to attract many of the world’s most prominent ocular health experts.\r\n \r\n Three-Year Myopia Control Efficacy of DOTTM Spectacle Lenses in Young Children (Laughton D., et al.) centers on a sub-group six-to-seven-year-olds who participated in the company’s pivotal CYPRESS clinical trial, with investigators noting expectations of highly progressive myopia and a paucity of efficacy data for this age group. After three years, myopia progression among these young children was limited to <1.00 D in 60% of Diffusion Optics TechnologyTM 0.2 spectacle lens wearers compared to 21% of control lens wearers. This data— shared for the first time in Manchester—further supports previously announced safety and efficacy outcomes.\r\n \r\n Reliability of Quality of Vision Questionnaire Results from Children (McParland M., et al.) assessed pediatric application of the Quality of Vision (QoV) questionnaire, which is more commonly used for adult refractive surgery and intraocular lens research. Investigators abbreviated the standard QoV instrument to focus on glare, hazy vision, and halos, then analyzed responses from CYPRESS clinical trial participants and from their parents/guardians across three years. The greater consistency of within-child agreement compared to parent- child response agreement suggests that parents may under-report their children’s experiences, while also affirming that children as young as age six can share meaningful QoV- derived insights to help inform clinical decisions.\r\n \r\n Peripheral Visual Function with DOT Spectacle Lenses for Myopia Control (Aboualizadeh E., et al.) debuts at the BCLA meeting, tapping into the rich CYPRESS data set to review long-term changes in peripheral visual acuity (VA) after three years of Diffusion Optics TechnologyTM spectacle lens wear. Compared to the baseline, peripheral VA improved or remained stable, with no significant differences between the DOT and standard single-vision groups.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n SightGlass Vision has also organized one of eight prominent peer review track sessions at the conference on Saturday: How Do Myopia Management Therapies Work and Does It Matter?, led by global myopia experts Prof. Nicola Logan and Prof. James Wolffsohn. Anticipated high demand for the session requires pre-booking from attendees.\r\n \r\n “We are deeply committed to advancing myopia control, evidenced by our presentations at the BCLA Conference plus recent efficacy, safety, and visual performance data reporting at ARVO in North America and COOC in China. Eye care professionals can confidently prescribe Diffusion Optics TechnologyTM spectacle lenses, knowing the outcomes are supported by extensive science,” said Andrew Sedgwick, CEO of SightGlass Vision.\r\n \r\n Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy,1,2,3 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n For more information, visit SightGlassVision.com\r\n \r\n SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n \r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><strong>Media Contact</strong></p>\r\n <p style="text-align: center;">Mike McDougall, APR, Fellow PRSA,\r\n FAAO McDougall Communications for SightGlass Vision\r\n +1-585-434-2150 or mike@mcdougallpr.com</p>\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_title: "SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conference" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference" +to_ping: "" +pinged: "" +post_modified: "2023-06-30 11:40:24" +post_modified_gmt: "2023-06-30 09:40:24" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=770" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 770 +"slug": "sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference" +"custom": array:27 [ "_edit_lock" => "1692707136:4" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ REFERENCES\r\n \r\n 1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 2 Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 3 Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-07" "_thumbnail_id" => "1111" ] } 5 => WP_Post {#2545 +ID: 769 +post_author: "1" +post_date: "2023-04-23 12:11:42" +post_date_gmt: "2023-04-23 10:11:42" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><em>Studies Presented at ARVO 2023 Analyze and Evaluate Multiple Performance Characteristics, Including Positive 42-Month CYPRESS Axial Length and SER Outcomes</em></p>\r\n <strong>LOS ALTOS, CALIF., April 23, 2023</strong> - SightGlass Vision today announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics TechnologyTM spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Meeting in New Orleans.\r\n \r\n Most prominent is the reporting of 42-month data from the company’s pivotal CYPRESS study extension. Results reinforced the safety and efficacy of Diffusion Optics TechnologyTM spectacle lenses in children aged 6–10 at the study’s start.1 The latest investigation re- enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial to generate six additional months of data. Outcomes again demonstrated statistically significant improvements in axial length (AL) and cycloplegic spherical equivalent refraction (cSER) between the test and control groups.\r\n \r\n Separate work calculated age-independent myopia AL growth to evaluate Diffusion Optics TechnologyTM spectacle lens efficacy.2 Because AL growth occurs even in persistently emmetropic eyes as a child develops and is most rapid before preadolescence, deriving an age-adjusted measure is valuable for clinicians and researchers. Physiological AL growth was determined based on age-matched emmetropic eye growth data from the Orinda Longitudinal Study of Myopia3, then compared to AL growth observed in the original three- year CYPRESS study. Children in the test lens group showed 0.23 mm (73%, p=0.003) less pathological AL change than the control group (test: 0.08 ± 0.06 mm; control: 0.31 ± 0.05 mm).\r\n \r\n “The extensive and rigorous science we are communicating at ARVO 2023 demonstrates the depth of our commitment to advancing myopia control, while also building additional confidence in the efficacy, safety, and overall performance of Diffusion Optics TechnologyTM spectacle lenses,” said Andrew Sedgwick, CEO of SightGlass Vision.\r\n \r\n In addition to the featured CYPRESS presentations, SightGlass Vision and its research partners will display several scientific posters at the meeting. A study from the Centre for Ocular Research & Education (CORE) shows that Diffusion Optics TechnologyTM spectacle lenses have no significant effect on accommodative lag after short-term wear.4 Work from Indiana University suggests that Diffusion Optics TechnologyTM contrast-reducing micro-dots do not limit high quality spatial details and good visual performance5, while another Indiana investigation concludes that wearers are unlikely to notice substantial contrast decreases when looking through the spectacle lens treatment zone.6 A SightGlass team also examined the effect of social restrictions during the COVID-19 pandemic on myopia progression in North American children who participated in the CYPRESS study.7\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to soften contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy1ᣟ2ᣟ8ᣟ9ᣟ10 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n For more information, visit SightGlassVision.com.\r\n \r\n <strong>About SightGlass Vision</strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics TechnologyTM is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_title: "New SightGlass Vision Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology™ Spectacle Lenses at ARVO 2023" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "new-sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technologytm-spectacle-lenses" +to_ping: "" +pinged: "" +post_modified: "2023-07-06 17:17:13" +post_modified_gmt: "2023-07-06 15:17:13" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=769" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 769 +"slug": "new-sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technologytm-spectacle-lenses" +"custom": array:27 [ "_edit_lock" => "1688658306:1" "_edit_last" => "1" "_wp_old_date" => "2023-06-07" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ <div class="layoutArea">\r\n <div class="column">\r\n \r\n REFERENCES\r\n \r\n </div>\r\n </div>\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n 1. Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 2. Laughton D., et al. Calculated age-independent myopic axial length growth in the CYPRESS clinical trial. ARVO 2023 Annual Meeting presentation. 26 April 2023.\r\n \r\n 3. Jones et al. Comparison of ocular component growth curves among refractive error groups in children, Invest Ophthalmol Vis Sci. 2005;46:2317-2327\r\n \r\n 4. Jabeen A., et al. Evaluation of the Lag of accommodation with DOT spectacle lenses. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 5. Gantes-Nuñez, F., et al. Optical Characterization of a Diffusion Optics Technology Ophthalmic Lens Designed for Myopia Control. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 6. MeyerD.,etal.Evaluation of Contrast Sensitivity with Diffusion Optics Technology Lenses. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 7. McParland, M., et al. Myopia progression before, during and after the COVID-19 pandemic in North American children. ARVO 2023 Annual Meeting presentation. 23 April 2023.\r\n \r\n 8. Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 9. Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 10. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S.\r\n \r\n </div>\r\n </div> """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_thumbnail_id" => "1197" ] } 6 => WP_Post {#2544 +ID: 768 +post_author: "1" +post_date: "2023-04-12 12:11:07" +post_date_gmt: "2023-04-12 10:11:07" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><em>Companies Present Enhanced Lenses, Key Trials Results and Case Reviews in Collaboration with Top Chinese Eye Care Professionals</em></p>\r\n <strong>LOS ALTOS, CALIF., April 12, 2023</strong>—SightGlass Vision will share its innovative myopia control spectacle lens technology at the International Congress of Ophthalmology and Optometry China (COOC), in partnership with Nikon Lenswear. The conference takes place in Shanghai from April 14-16, 2023, attracting the country’s most prominent eye care clinicians, researchers, and educators.\r\n \r\n Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy1,2,3 made its commercial debut in several markets, including China. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n During COOC, SightGlass Vision and Nikon Lenswear will demonstrate the latest lens iteration, featuring enhanced aesthetics that make the micro-dots less visible during everyday wear. In addition, Marcella McParland and Lucill Wang from the SightGlass Vision Clinical, Medical and Professional Affairs team will present side by side with several ophthalmology key opinion leaders, including Dr. Peter Chen from Shanghai ENT and Dr. Liu Longqian from West China Center of Medical Sciences of Sichuan University, to present multiple case reviews and explain results from its multi-year CYPRESS clinical trial. The company has also begun a separate clinical trial in China.\r\n \r\n “Since our launch with Nikon in China several months ago, momentum has continued to grow,” said Andrew Sedgwick, CEO of SightGlass Vision. “No other country has the depth of understanding and awareness of myopia’s impact on society as China, nor the experience of its clinical community with the disease. Our introduction of new, evidence-based Diffusion Optics TechnologyTM to help reach aneven larger segment of children has been widely embraced—something we expect to see first-hand\r\n \r\n at COOC.”\r\n \r\n The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly five billion people—half the world’s population—will be myopic by 2050. 4 Uncorrected myopia is the leading cause of visual impairment in children. Over time, its progression may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia5.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n In addition to China, spectacle lenses with Diffusion Optics Technology are currently available in the Netherlands and Israel, as well as through preliminary market trials in other countries. For more information, visit SightGlassVision.com.\r\n \r\n For more information, visit SightGlassVision.com.\r\n \r\n About SightGlass Vision\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics TechnologyTM is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n \r\n \r\n \r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><strong>Media Contact</strong></p>\r\n <p style="text-align: center;">Mike McDougall, APR, Fellow PRSA,\r\n FAAO McDougall Communications for SightGlass Vision\r\n +1-585-434-2150 or mike@mcdougallpr.com</p>\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_title: "SightGlass Vision Highlights New Myopia Control Spectacle Lens Technology at COOC 2023" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology-at-cooc" +to_ping: "" +pinged: "" +post_modified: "2023-06-30 11:41:11" +post_modified_gmt: "2023-06-30 09:41:11" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=768" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 768 +"slug": "sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology-at-cooc" +"custom": array:27 [ "_edit_lock" => "1688656425:1" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ REFERENCES\r\n \r\n 1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published. Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 2 Joe Rappon, Jay Neitz, Maureen Neitz, Carol Chung, Thomas Walter Chalberg; Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408\r\n \r\n 3 A 36-month clinical trial demonstrated safety and efficacy for children ages six to 10 at enrolment, significantly reducing both axial length and cycloplegic SER progression versus the control. The study has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, three-arm parallel group clinical trial with diverse subjects reflecting the U.S. population. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n 4 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-42\r\n \r\n 5 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-07" "_thumbnail_id" => "1112" ] } 7 => WP_Post {#2543 +ID: 418 +post_author: "1" +post_date: "2022-10-24 11:05:40" +post_date_gmt: "2022-10-24 09:05:40" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><em>Diffusion Optics TechnologyTM Effective for Young Children;</em>\r\n <em>Complete Results Presented at 2022 American Academy of Optometry Meeting</em></p>\r\n <strong>LOS ALTOS, CALIF., October 24, 2022</strong>—Analysis of 36-month data from the pivotal CYPRESS myopia control clinical trial has demonstrated the safety and efficacy of SightGlass VisionTM spectacle lenses with Diffusion Optics TechnologyTM for children ages six to 10 years at enrollment. The intervention significantly reduced both axial length and cycloplegic SER progression versus the control.\r\n \r\n Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years (Laughton, D et al) will be presented at the 2022 American Academy of Optometry annual meeting in San Diego on Thursday, October 27.*\r\n \r\n In addition to illustrating myopia control efficacy, 36-month data showed low device-related adverse event rates. No serious adverse events were reported. Visual performance for distance and near was excellent (20/20 or better) and remained stable, and low contrast visual acuity was similar to control. While the lens proved beneficial at all ages, the slowing of myopia progression among children ages six to seven years at the initiation of treatment is of particular note.\r\n \r\n “There are currently no other interventions with this degree of demonstrated efficacy for six- and seven-year-old children, even though more severe adult myopia is generally linked to earlier onset,” said Andrew Sedgwick, CEO of SightGlass Vision. “We purposefully enrolled a subset of younger children to examine this gap in myopia control research and treatment options. With its unique mechanism of action, our Diffusion Optics Technology is a new approach and represents a first line of defense for young myopes.”\r\n \r\n Lenses that incorporate SightGlass Vision Diffusion Optics Technology use thousands of micro- dots that softly scatter light to reduce contrast on the retina and are designed to reduce myopia progression in children.\r\n \r\n CYPRESS has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, diverse study population reflecting the U.S. population, three-arm parallel group clinical trial. During the paper presentation, researchers will also share early observations from the CYPRESS extension study, which tracks clinical results beyond the 36-month mark.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n IThe last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly five billion people—half the world’s population—will be myopic by 2050.1 Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased riskof developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.2\r\n \r\n DOT 0.2 spectacle lenses are not approved in the United States. ###\r\n \r\n *Academy attendees can attend the Safety and Efficacy of a Novel Spectacle Lens for Myopia\r\n Control Over Three Years paper presentation at 3:15 p.m. PT on Thursday, Oct. 27 in the San Diego Convention Center, Upper Level, Room 29CD.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n \r\n \r\n \r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><strong>Media Contact</strong></p>\r\n <p style="text-align: center;">Mike McDougall, APR, Fellow PRSA, FAAO\r\n McDougall Communications for SightGlass Vision\r\n +1-585-434-2150 or mike@mcdougallpr.com</p>\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_title: "SightGlass Vision Spectacles Reduce Myopia Progression in Children, According to Three Year Clinical Study Data - AAO 2023" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-unveils-topline-data-from-cypress-pivotal-study-of-novel-eyeglasses" +to_ping: "" +pinged: "" +post_modified: "2023-06-27 09:38:54" +post_modified_gmt: "2023-06-27 07:38:54" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=418" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 418 +"slug": "sightglass-vision-unveils-topline-data-from-cypress-pivotal-study-of-novel-eyeglasses" +"custom": array:27 [ "_edit_last" => "2" "_edit_lock" => "1688656426:1" "_thumbnail_id" => "1002" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ REFERENCES\r\n \r\n 1 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 23(5):1036-42\r\n \r\n 2 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_yoast_wpseo_content_score" => "30" "_wp_old_date" => array:2 [ 0 => "2023-05-03" 1 => "2023-04-12" ] ] } 8 => WP_Post {#2542 +ID: 914 +post_author: "2" +post_date: "2022-09-01 10:27:38" +post_date_gmt: "2022-09-01 08:27:38" +post_content: """ <b><span data-contrast="auto">LOS ALTOS, CALIF., 1 September 2022</span></b><span data-contrast="auto">—When the 18</span><span data-contrast="auto">th</span><span data-contrast="auto"> International Myopia Conference (IMC) opens in Rotterdam next week, it will mark a series of milestones for one of the most promising technology companies in the category. For the first time, SightGlass Vision will exhibit at the meeting, in addition to presenting additional data and insights related to its Diffusion Optics Technology</span><span data-contrast="auto">™</span><span data-contrast="auto"> as well as CYPRESS clinical trial, including preliminary three-year results findings.</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-ccp-props="{"335551550":6,"335551620":6}"> </span><span data-contrast="auto">Spectacle lenses using patent-protected SightGlass Vision</span><span data-contrast="auto">™</span><span data-contrast="auto"> Diffusion Optics Technology</span><span data-contrast="auto">™️</span><span data-contrast="auto"> incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">“SightGlass Vision is now fully operational. Our entire leadership group is in place, and we are making good progress on commercial launches in markets such as China, Israel, and the Netherlands, with more to come,” said Andrew Sedgwick, the company’s CEO. “Enthusiastic reaction to our latest data analysis on younger children enrolled in CYPRESS, which suggests we have a promising approach to myopia control for children as early as age six, is inspiring—to our team and the eye care profession. We’re looking forward to discussing those findings in even greater depth at the IMC.” </span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">Younger ages are of particular interest to eye care professionals and researchers, since myopia progresses fastest in the youngest children.¹,²</span><span data-contrast="auto"> Because progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health. </span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">On Sunday, 4 September, at 12:40 pm CET, SightGlass Vision will host an all-attendee luncheon session on contrast theory and the Science behind Diffusion Optics Technology™. </span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">Its researchers will also participate in the Optical Interventions session on Tuesday 6 September at 8:45 am CET, presenting </span><i><span data-contrast="auto">The Visual Performance with N</span></i><i><span data-contrast="auto">ovel Spectacle Lenses for Myopia Control</span></i><span data-contrast="auto"> (Laughton D, et al.). After three years, children wearing the lenses with Diffusion Optics Technology</span><span data-contrast="auto">™️</span><span data-contrast="auto"> demonstrated significantly less myopia progression than the control group. The novel spectacle lenses provided good all-round visual performance and were well tolerated for the study duration.</span><span data-contrast="auto">³</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">The company is a gold sponsor of the 2022 IMC, joining other global organizations in addressing the global myopia epidemic.</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people—half the world’s population—will be myopic by 2050.₄</span><span data-contrast="auto"> Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁵</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n <p style="text-align: center;"># # #</p>\r\n <strong><u>About SightGlass Vision</u></strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-434-2150 or mike@mcdougallpr.com\r\n \r\n \r\n <ol>\r\n \t<li>Hyman L, et al. <em>Relationship of Age, Sex, and Ethnicity with Myopia Progression and Axial Elongation in the Correction of Myopia Evaluation Trial</em>. Archives of Ophthalmology. 2005;123(7):977 987.</li>\r\n \t<li>Verkicharla PK, Kammari P, Das AV. <em>Myopia progression varies with age and severity of myopia</em>. PLOS ONE. 2020;15(11):e0241759.</li>\r\n \t<li>SGV data on file 2022. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 3-Year Final Report (n = 256, 14 North American sites).</li>\r\n \t<li>Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. <em>Ophthalmology</em> 2016. 123(5):1036-42</li>\r\n \t<li>Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. <em>JAMA Ophthalmol</em>. 2016;134:1355-1363</li>\r\n </ol> """ +post_title: "SightGlass Vision Celebrates Major Milestones at IMC 2022" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-celebrates-major-milestones-at-imc-2022" +to_ping: "" +pinged: "" +post_modified: "2023-06-30 11:41:38" +post_modified_gmt: "2023-06-30 09:41:38" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=914" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 914 +"slug": "sightglass-vision-celebrates-major-milestones-at-imc-2022" +"custom": array:27 [ "_edit_lock" => "1688656426:1" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_thumbnail_id" => "1110" "_wp_old_date" => "2023-06-23" ] } 9 => WP_Post {#2537 +ID: 916 +post_author: "2" +post_date: "2022-06-23 10:35:45" +post_date_gmt: "2022-06-23 08:35:45" +post_content: """ <strong>PALO ALTO, CALIF., June 23, 2022</strong>—Analysis of 24-month interim data from the pivotal CYPRESS clinical trial is offering increased hope for controlling myopia progression among young children. Spectacles that use SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™</sup> were shown to significantly reduce both axial length (mean absolute reduction = 0.27 mm) and cycloplegic SER progression (mean absolute reduction = 0.77 D) in six- and seven-year-old children versus the control.*\r\n \r\n <em>Two Year Effectiveness of a Novel Myopia Management Spectacle Lens in Young Myopes </em>(Rappon J, Neitz J, Neitz M, Chalberg T) will be presented for the first time at the 2022 Dutch Contact Lens Congress (NCC), which begins next week in Eindhoven, The Netherlands.\r\n \r\n The focus on age is of particular interest to eye care professionals and researchers, as myopia progresses fastest in the youngest children.<sup>¹,²</sup> Since progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health.\r\n \r\n “Young myopes can be difficult to manage for many reasons. Parents and eye care professionals have traditionally had a limited number of myopia control solutions for younger children,” said Andrew Sedgwick, CEO of SightGlass Vision. “Our latest analysis suggests that spectacles enabled with SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™</sup> offer a promising new approach to myopia control for six- and seven-year-olds.”\r\n \r\n Study investigators enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada—a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D, with nearly a third of them being six or seven years old. With a mean age of 8.1 years at screening, the entire CYPRESS cohort is younger than children in many other well-known myopia management studies across various interventions. The trial is now in its third year.\r\n \r\n Spectacle lenses using patent-protected SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™️</sup> incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.\r\n \r\n The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people—half the world’s population—will be myopic by 2050.³ Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁴\r\n \r\n \r\n <p style="text-align: center;"># # #</p>\r\n <strong><u>About SightGlass Vision</u></strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-434-2150 or mike@mcdougallpr.com\r\n \r\n <a href="#_ednref1" name="_edn1">[1]</a> Hyman L, et al. <em>Relationship of Age, Sex, and Ethnicity with Myopia Progression and Axial Elongation in the Correction of Myopia Evaluation Trial</em>. Archives of Ophthalmology. 2005;123(7):977 987.\r\n \r\n <a href="#_ednref2" name="_edn2">[2]</a> Verkicharla PK, Kammari P, Das AV. <em>Myopia progression varies with age and severity of myopia</em>. PLOS ONE. 2020;15(11):e0241759.\r\n \r\n <a href="#_ednref3" name="_edn3">[3]</a> Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. <em>Ophthalmology</em> 2016. 123(5):1036-42\r\n \r\n <a href="#_ednref4" name="_edn4">[4]</a> Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. <em>JAMA Ophthalmol</em>. 2016;134:1355-1363 """ +post_title: "SightGlass Vision Spectacles Control Myopia Progression for 6- and 7-Year-Olds, According to New Data Analysis - NCC2022" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "sightglass-vision-spectacles-control-myopia-progression-for-6-and-7-year-olds-according-to-new-data-analysis-ncc2022" +to_ping: "" +pinged: "" +post_modified: "2023-07-06 17:18:54" +post_modified_gmt: "2023-07-06 15:18:54" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=916" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 916 +"slug": "sightglass-vision-spectacles-control-myopia-progression-for-6-and-7-year-olds-according-to-new-data-analysis-ncc2022" +"custom": array:27 [ "_edit_lock" => "1688658307:1" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-23" "_thumbnail_id" => "1197" ] } 10 => WP_Post {#2889 +ID: 915 +post_author: "2" +post_date: "2022-05-02 10:32:24" +post_date_gmt: "2022-05-02 08:32:24" +post_content: """ <strong>PALO ALTO, CALIF., May 2, 2022</strong>—Spectacles that use SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™</sup> have demonstrated efficacy in slowing the progression of myopia in children,¹ based on 24-month interim data from its pivotal clinical trial data presented this week at ARVO 2022.\r\n \r\n <em>Two Year Effectiveness of a Novel Myopia Management Spectacle Lens with Full Time Wearers </em>(Rappon J, Neitz J, Neitz M , Chung C, Chalberg T) is a featured presentation at the annual conference, which is attended by thousands of the world’s most respected ophthalmology, optometry, and vision science researchers.\r\n \r\n An analysis of full-time wearers—children ages 6-10 at initiation whose parents reported that they did not remove the study spectacles for near vision activities —showed statistically significant improvements between groups using Diffusion Optics Technology<sup>™</sup> lenses and the control. Axial length exhibited a 0.21 mm difference, and the spherical equivalent refraction difference was 0.52 D.\r\n \r\n Study investigators enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada—a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D. The CYPRESS trial is now in its third year.\r\n \r\n With a mean age of 8.1 years at screening, the CYPRESS cohort is younger than children in other well-known myopia management studies.<sup>²,³,⁴</sup> Given the higher likelihood of spectacles-based interventions for younger children, this study parameter should help build confidence in prescribers and families alike. Additional analysis of younger wearers will be presented at NCC 2022 this June.\r\n \r\n Spectacle lenses using patent-protected SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™️</sup> incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.\r\n \r\n “With their unique mechanism of action, Diffusion Optics Technology<sup>™</sup> spectacle lenses represent a promising new approach to myopia control,” said Andrew Sedgwick, CEO of SightGlass Vision. “We’re enthusiastic about sharing more detail from the two-year interim results, which will further support our development efforts and ongoing commercialization activities in select markets.”\r\n \r\n The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people – half the world’s population – will be myopic by 2050.⁵ Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁶\r\n <p style="text-align: center;"><u>###</u></p>\r\n <strong><u>About SightGlass Vision</u></strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-434-2150 or mike@mcdougallpr.com\r\n \r\n \r\n <ol>\r\n \t<li>Spectacles with SightGlass Vision Diffusion Optics Technology™ are not approved for sale within the United States.</li>\r\n \t<li>GwiazdaJ, Hyman L, Hussein M, et al. A Randomized Clinical Trial of Progressive Addition Lenses versus Single Vision Lenses on the Progression of Myopia in Children. <em>Invest OphthalmolVis Sci</em>. 2003;44(4):1492.</li>\r\n \t<li>Walline JJ, GaumeGiannoni A, Sinnott LT, et al. A Randomized Trial of Soft Multifocal Contact Lenses for Myopia Control: Baseline Data and Methods. <em>Optometry and Vision Science</em>. 2017;94(9):856-866.</li>\r\n \t<li>Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study. <em>Ophthalmology</em>. 2019;126(1):113-124.</li>\r\n \t<li>Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. <em>Ophthalmology</em> 2016. 123(5):1036-42</li>\r\n \t<li>Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. <em>JAMA Ophthalmol</em>. 2016;134:1355-1363</li>\r\n </ol> """ +post_title: "ARVO 2022: 24-Month Data Demonstrates Myopia Control Efficacy for SightGlass Vision Spectacle Lenses" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "arvo-2022-24-month-data-demonstrates-myopia-control-efficacy-for-sightglass-vision-spectacle-lenses" +to_ping: "" +pinged: "" +post_modified: "2023-07-06 17:19:01" +post_modified_gmt: "2023-07-06 15:19:01" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?post_type=press_releases&p=915" +menu_order: 0 +post_type: "press_releases" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 915 +"slug": "arvo-2022-24-month-data-demonstrates-myopia-control-efficacy-for-sightglass-vision-spectacle-lenses" +"custom": array:27 [ "_edit_lock" => "1691671589:4" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "4" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-23" "_thumbnail_id" => "1197" ] } ] +post_count: 11 +current_post: -1 +before_loop: true +in_the_loop: false +post: WP_Post {#2550} +comment_count: 0 +current_comment: -1 +found_posts: 11 +max_num_pages: 1 +max_num_comment_pages: 0 +is_single: false +is_preview: false +is_page: false +is_archive: false +is_date: false +is_year: false +is_month: false +is_day: false +is_time: false +is_author: false +is_category: false +is_tag: false +is_tax: false +is_search: false +is_feed: false +is_comment_feed: false +is_trackback: false +is_home: true +is_privacy_policy: false +is_404: false +is_embed: false +is_paged: false +is_admin: false +is_attachment: false +is_singular: false +is_robots: false +is_favicon: false +is_posts_page: false +is_post_type_archive: false -query_vars_hash: "a8c5ae35cc9cc6bff28c88f168d5e962" -query_vars_changed: false +thumbnails_cached: false #allow_query_attachment_by_filename: false -stopwords: null -compat_fields: array:2 [ 0 => "query_vars_hash" 1 => "query_vars_changed" ] -compat_methods: array:2 [ 0 => "init_query_flags" 1 => "parse_tax_query" ] } -_posts_class: "\Timber\Post" } #pagination: Timber\Pagination {#3065 +current: 1 +total: 1.0 +pages: [] +next: null +prev: "" } -storage: array:11 [ 0 => Timber\Post {#2888 +id: 1366 +ID: 1366 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:50 [ "_edit_lock" => "1728303459:7" "_edit_last" => "7" "content_0_text" => """ <h1>Block "Rich text"</h1>\r\n Content > Rich text\r\n \r\n b<strong>old </strong><em>italic </em><a href="#tata">link</a>\r\n <h1></h1> """ "_content_0_text" => "field_65785f61cbff7" "content" => array:5 [ 0 => "rich-text" 1 => "image" 2 => "image" 3 => "content-image" 4 => "content-image" ] "_content" => "field_65785f1ecbff6" "video_poster" => "1201" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "1368" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "1210" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "Block "Push (Link)"" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => array:3 [ "title" => "CTA" "url" => "https://sgv.disko.love/the-prevention-of-eye-disease-in-children-4-top-tips/" "target" => "" ] "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "custom" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "Mentions" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_estimated-reading-time-minutes" => "1" "content_1_image" => "1125" "_content_1_image" => "field_65785f7acbffa" "content_1_size" => "medium" "_content_1_size" => "field_65785f87cbffb" "content_3_image" => "1127" "_content_3_image" => "field_65785fe3cbffe" "content_3_text" => "Block "Content + Image" 50/50" "_content_3_text" => "field_65785ff8cc000" "content_3_disposition" => "equal" "_content_3_disposition" => "field_65786012cc001" "content_2_image" => "1125" "_content_2_image" => "field_65785f7acbffa" "content_2_size" => "small" "_content_2_size" => "field_65785f87cbffb" "related_news" => array:2 [ 0 => "1302" 1 => "1300" ] "_related_news" => "field_644bbb809ed4d" "_thumbnail_id" => "1127" "content_4_image" => "1127" "_content_4_image" => "field_65785fe3cbffe" "content_4_text" => "Block "Content + Image" 25/75" "_content_4_text" => "field_65785ff8cc000" "content_4_disposition" => "small" "_content_4_disposition" => "field_65786012cc001" ] #___content: null #_permalink: "https://sgv.disko.love/releases/test/" #_next: [] #_prev: [] #_css_class: null +post_author: "7" +post_content: "" +post_date: "2024-09-19 17:37:57" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "Test" +post_type: "press_releases" +slug: "test" #__type: null +"_edit_lock": "1728303459:7" +"_edit_last": "7" +"content_0_text": """ <h1>Block "Rich text"</h1>\r\n Content > Rich text\r\n \r\n b<strong>old </strong><em>italic </em><a href="#tata">link</a>\r\n <h1></h1> """ +"_content_0_text": "field_65785f61cbff7" +"_content": "field_65785f1ecbff6" +"video_poster": "1201" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "1368" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "1210" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "Block "Push (Link)"" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": array:3 [ "title" => "CTA" "url" => "https://sgv.disko.love/the-prevention-of-eye-disease-in-children-4-top-tips/" "target" => "" ] +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "custom" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": "Mentions" +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_estimated-reading-time-minutes": "1" +"content_1_image": "1125" +"_content_1_image": "field_65785f7acbffa" +"content_1_size": "medium" +"_content_1_size": "field_65785f87cbffb" +"content_3_image": "1127" +"_content_3_image": "field_65785fe3cbffe" +"content_3_text": "Block "Content + Image" 50/50" +"_content_3_text": "field_65785ff8cc000" +"content_3_disposition": "equal" +"_content_3_disposition": "field_65786012cc001" +"content_2_image": "1125" +"_content_2_image": "field_65785f7acbffa" +"content_2_size": "small" +"_content_2_size": "field_65785f87cbffb" +"related_news": array:2 [ 0 => "1302" 1 => "1300" ] +"_related_news": "field_644bbb809ed4d" +"_thumbnail_id": "1127" +"content_4_image": "1127" +"_content_4_image": "field_65785fe3cbffe" +"content_4_text": "Block "Content + Image" 25/75" +"_content_4_text": "field_65785ff8cc000" +"content_4_disposition": "small" +"_content_4_disposition": "field_65786012cc001" +"post_date_gmt": "2024-09-19 15:37:57" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "test" +"to_ping": "" +"pinged": "" +"post_modified": "2024-10-07 14:19:21" +"post_modified_gmt": "2024-10-07 12:19:21" +"post_content_filtered": "" +"guid": "https://sgv.disko.love/?post_type=press_releases&p=1366" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 1 => Timber\Post {#2890 +id: 1260 +ID: 1260 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:26 [ "_edit_lock" => "1726843767:7" "_edit_last" => "1" "_thumbnail_id" => "1261" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "5" "_yoast_wpseo_wordproof_timestamp" => "" ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-presents-new-data-at-academy-23-reinforcing-diffusion-optics-technology-myopia-control-impact/" #_next: [] #_prev: [] #_css_class: null +post_author: "2" +post_content: """ <p style="text-align: center;"><em>CYPRESS 48-Month Efficacy Study, Prof Wolffsohn Visual Experience Study, and Dr. Ho Real-World Clinical Records Review Further Strengthen Evidence Base for DOT 0.2 Spectacle Lenses.</em></p>\r\n \r\n \r\n <strong>NEW ORLEANS, October 9, 2023</strong>—Findings from three <a href="http://sgv.disko.love/">SightGlass Vision</a> Diffusion Optics Technology<sup>™ </sup>(DOT 0.2) spectacle lenses studies will take center stage at the American Academy of Optometry 2023 Annual Meeting, which opens this week in New Orleans. Individually and collectively, they reinforce the robust performance of the company’s flagship myopia control intervention, which uses thousands of light scattering elements called dots to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.\r\n \r\n \r\n \r\n In-depth data from <a href="https://eppro02.ativ.me/web/index.php?page=Session&project=AAOPT23&id=P-03-03"><strong><em>Control of Myopia Using Diffusion Optics Technology Spectacle Lenses: 4-Year Results</em></strong><strong> <em>(CYPRESS)</em></strong></a> are being presented by Dr. Debbie Laughton on October 11, demonstrating statistically significant slowing of axial length (AL) progression and cycloplegic spherical equivalent refraction (cSER). Expanding on <a href="http://sgv.disko.love/releases/sightglass-vision-reports-positive-four-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/">top line findings shared last month</a> from the rigorous, multi-site study, researchers report that children wearing their DOT 0.2 spectacles full-time continue to show substantial clinical benefit over 48 months.\r\n \r\n \r\n \r\n Among the additional data reported at Academy ’23 is visual performance among CYPRESS participants over the four-year span. Mean binocular high contrast LogMAR visual acuity (VA) measurements were clinically stable and similar between groups at distance (test -0.09 ± 0.08, control -0.07 ± 0.06) and near (test -0.03 ± 0.14, control -0.04 ± 0.10). Mean monocular low contrast (10%) distance VA showed an improvement over the course of the study (mean change from baseline: test 0.05 ± 0.12, control 0.07 ± 0.11), and mean peripheral VA improved or remained similar in all quadrants, with no significant differences between treatment groups.\r\n \r\n \r\n \r\n The CYPRESS paper has been selected by the Academy as one of the six most newsworthy presentations scheduled for New Orleans. Dr. Laughton will summarize the work during the Academy-hosted Innovations in Vision and Eye Care event on Wednesday, October 11.\r\n \r\n \r\n \r\n A companion study co-developed by esteemed researcher and Professor James Wolffsohn of Aston University assessed the <a href="https://eppro02.ativ.me/web/index.php?page=Session&project=AAOPT23&id=Board-131"><strong><em>Visual Impact of Diffusion Optics Technology Lenses for Myopia Control</em></strong></a>. Children (12.2±1.3 years old, range 10-14, 51% female) were randomly assigned to wear DOT 0.2 spectacle lenses (n=27) or single vision lenses (n=24) for 3.5 years across six North American sites. Investigators determined that the DOT 0.2 lens provides an equivalent visual experience to a standard single vision lens, as evaluated through binocular high and low contrast distance visual acuities, near visual acuity, reading speed, contrast sensitivity, stereoacuity and glare measures.\r\n \r\n \r\n \r\n Presented by Dr. Kylvin Ho of C U Vision Optometrists (Vancouver), <a href="https://eppro02.ativ.me/web/index.php?page=Session&project=AAOPT23&id=Board-130"><strong><em>Real-World Effectiveness of Diffusion Optics Technology (DOT) Spectacle Lenses for Myopia Control in Chinese Canadian Children</em></strong></a> identified 39 patients who were prescribed the intervention as a monotherapy between October 2020 to December 2022 in an independent practice. After 12 months, mean progression was -0.28 ± 0.32 D in SER (n=39) and 0.15 ± 0.17 mm in AL (n=36). SER progression was limited to -0.25 D or less in 56% of children during the time frame.\r\n \r\n \r\n \r\n Compared to Singapore Cohort Study of the Risk Factors for Myopia (SCORM) data, DOT 0.2 lenses slowed AL progression by 62% (0.24 mm). The 12-month AL elongation was similar to 0.14 mm SCORM-predicted, age-matched emmetropic eye growth (physiological eye growth). The Canadian practice data also aligned with CYPRESS study 12-month outcomes of 0.15 mm AL progression.\r\n \r\n \r\n \r\n “Myopia progression is one of the greatest health epidemics of our time, deserving of attention and resources from researchers, educators, and policy makers. The evidence-based efficacy and impact of Diffusion Optics Technology<sup>™</sup> spectacle lenses, clearly and convincingly demonstrated across multiple dimensions at Academy ’23, shows their substantial potential to change the lives of children around the world. We thank the Academy for recognizing CYPRESS as among the most compelling and robust science to be presented this year, and we look forward to sharing more with colleagues over the coming days,” said Andrew Sedgwick, CEO of SightGlass Vision.\r\n \r\n \r\n \r\n Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy<a href="#_edn1" name="_ednref1">[i]</a><sup>,</sup><a href="#_edn2" name="_ednref2">[ii]</a><sup>,</sup><a href="#_edn3" name="_ednref3">[iii]</a> made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n \r\n \r\n For more information, visit <a href="http://sgv.disko.love">SightGlassVision.com</a>.\r\n \r\n <strong>About SightGlass Vision</strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n <em>SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.</em>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA, FAAO\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-545-1815 or mike@mcdougallpr.com\r\n \r\n \r\n \r\n <a href="#_ednref1" name="_edn1">[i]</a> Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n \r\n \r\n <a href="#_ednref2" name="_edn2">[ii]</a> Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n \r\n \r\n <a href="#_ednref3" name="_edn3">[iii]</a> Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022. """ +post_date: "2023-10-09 13:53:53" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Presents New Data at Academy ’23, Reinforcing Diffusion Optics Technology™ Myopia Control Impact" +post_type: "press_releases" +slug: "sightglass-vision-presents-new-data-at-academy-23-reinforcing-diffusion-optics-technology-myopia-control-impact" #__type: null +"_edit_lock": "1726843767:7" +"_edit_last": "1" +"_thumbnail_id": "1261" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": "" +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "5" +"_yoast_wpseo_wordproof_timestamp": "" +"post_date_gmt": "2023-10-09 11:53:53" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-presents-new-data-at-academy-23-reinforcing-diffusion-optics-technology-myopia-control-impact" +"to_ping": "" +"pinged": "" +"post_modified": "2023-10-24 10:55:21" +"post_modified_gmt": "2023-10-24 08:55:21" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=1260" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 2 => Timber\Post {#2891 +id: 1253 +ID: 1253 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:26 [ "_edit_lock" => "1698138530:1" "_edit_last" => "1" "_thumbnail_id" => "1197" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "60" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-releases-first-white-paper-on-diffusion-optics-technology/" #_next: [] #_prev: [] #_css_class: null +post_author: "2" +post_content: """ <strong>LOS ALTOS, CALIF., September 20, 2023</strong>—<a href="http://sgv.disko.love/">SightGlass Vision</a> today announced the release of its <a href="http://sgv.disko.love/resources-for-eye-care-professionals/">first white paper</a> regarding the company’s Diffusion Optics Technology<sup>™ </sup>(DOT 0.2) spectacle lenses. The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.\r\n \r\n \r\n \r\n The in-depth paper explains the relationship between artificially high contrast signals at the retina and myopia progression. This groundbreaking research led to the development of DOT to manage such contrast, now clinically proven via the pivotal CYPRESS study to slow myopia progression in children from age six. Its efficacy is particularly of note for the youngest patients, who would typically experience the fastest progression.\r\n \r\n \r\n \r\n The white paper can be read online or downloaded as a PDF at <a href="http://sgv.disko.love/resources-for-eye-care-professionals/">http://sgv.disko.love/resources-for-eye-care-professionals/</a>\r\n \r\n \r\n \r\n “Harnessing the power of contrast management is a revolutionary approach to controlling myopia. Our DOT spectacle lenses are now paving a new path to reducing myopia progression from an early age. This white paper goes deeper into the science to explain the mechanisms of action, helping eye care professionals better understand the innovation,” said SightGlass Vision Vice President of Clinical, Medical & Professional Affairs Marcella McParland.\r\n \r\n \r\n \r\n “As a more recent entrant into the myopia management field, our Diffusion Optics Technology paper will help disseminate the substantial science behind contrast management and its application. DOT spectacle lenses present a compelling alternative to existing solutions for slowing myopia’s progression in children,” added Andrew Sedgwick, SightGlass Vision’s CEO.\r\n \r\n \r\n \r\n Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy<sup>1,2,3,4</sup> made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n \r\n \r\n For more information, visit <a href="http://sgv.disko.love">SightGlassVision.com</a>.\r\n \r\n \r\n <ol>\r\n \t<li>Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.</li>\r\n </ol>\r\n \r\n <ol start="2">\r\n \t<li>Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005</li>\r\n </ol>\r\n \r\n <ol start="3">\r\n \t<li>Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.</li>\r\n </ol>\r\n \r\n <ol start="4">\r\n \t<li>Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.</li>\r\n </ol>\r\n \r\n <h5>About SightGlass Vision</h5>\r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <em>SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.</em>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA, FAAO\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-545-1815 or mike@mcdougallpr.com """ +post_date: "2023-09-20 14:54:01" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Releases First White Paper on Diffusion Optics Technology™" +post_type: "press_releases" +slug: "sightglass-vision-releases-first-white-paper-on-diffusion-optics-technology" #__type: null +"_edit_lock": "1698138530:1" +"_edit_last": "1" +"_thumbnail_id": "1197" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": "" +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "60" +"_yoast_wpseo_estimated-reading-time-minutes": "3" +"_yoast_wpseo_wordproof_timestamp": "" +"post_date_gmt": "2023-09-20 12:54:01" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-releases-first-white-paper-on-diffusion-optics-technology" +"to_ping": "" +"pinged": "" +"post_modified": "2023-10-24 11:07:09" +"post_modified_gmt": "2023-10-24 09:07:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=1253" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 3 => Timber\Post {#2892 +id: 1228 +ID: 1228 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:26 [ "_edit_lock" => "1726760119:7" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => "" "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "4" "_yoast_wpseo_wordproof_timestamp" => "" "_thumbnail_id" => "1229" ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-reports-positive-four-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/" #_next: [] #_prev: [] #_css_class: null +post_author: "2" +post_content: """ <p style="text-align: center;"><em>Compelling Axial Length and cSER Findings, Plus New Case Reviews from Chinese Children,\r\n Presented at the 27<sup>th</sup> Congress of the Chinese Ophthalmological Society</em></p>\r\n \r\n \r\n \r\n \r\n <strong>CHANGSHA, China, September 6, 2023</strong>—<a href="http://sgv.disko.love/">SightGlass Vision</a> today reported positive four-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology<sup>™ </sup>(DOT 0.2) spectacle lenses. The lenses use thousands of light scattering elements called dots, designed to mimic more natural contrast on the retina—a unique mechanism of action to slow myopia progression in children.\r\n \r\n \r\n \r\n The findings are being presented at the 27th Congress of the Chinese Ophthalmological Society (CCOS), held in Changsha, Hunan Province. Thousands of eye care clinicians, researchers, and educators from across China and overseas attend the biennial event.\r\n \r\n \r\n \r\n <em>Control of Myopia using Diffusion Optics Technology Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 4 Year Results</em> (Zhu X, McParland M, et al) affirmed DOT 0.2 safety and efficacy in children aged 6–10 at the study’s initiation.<sup>¹</sup> Part two of the study—designed to collect 12 additional months of data—re-enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial.\r\n \r\n \r\n \r\n Full four-year outcomes showed statistically significant slowing of axial length progression and cycloplegic spherical equivalent refraction (cSER), with the most recent data underscoring strong DOT 0.2 performance. During the 36- to 48-month timeframe, axial length mean change was 0.13 ±0.02 mm for the test group (n=55) and 0.18 ±0.02 mm for the control (n=41; p=0.038). cSER mean change was -0.25 ±0.04 D for the test group and -0.38 ±0.05 D for control (p=0.043).\r\n \r\n \r\n \r\n “<em>The CYPRESS four-year findings confirm the demonstrated efficacy, safety, and overall performance of Diffusion Optics Technology™ spectacle lenses</em>,” said Andrew Sedgwick, CEO of SightGlass Vision. “<em>Eye care professionals worldwide are demanding this level of scientific rigor, allowing them to confidently recommend the lenses to children and their caregivers. SightGlass Vision is proud to advance the myopia control category with our latest research and technologies, and enthusiastic about growing opportunities for spectacles in a child’s treatment regimen.</em>”\r\n \r\n \r\n \r\n A separate presentation at CCOS explored the theoretical basis and practical application of DOT lenses. <em>Discussion of DOT Lenses Based on Contrast Reduction Theory and Real-World Case Sharing</em> (Wang D, Xie P, Huang J) analyzed the influence of contrast in children's refractive development, the interaction between contrast signals and peripheral defocus signals, and the clinical performance of DOT lenses based on contrast reduction. Comparing existing studies with clinical observations of 117 Chinese children wearing DOT 0.2 lenses for 1 year, investigators concluded that contrast management , and that the lenses were effective and safe.\r\n \r\n \r\n \r\n Over the last two years, SightGlass Vision’s patent-protected technology with clinically proven efficacy<sup> ¹,²,³,⁴ </sup>made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n \r\n \r\n For more information, visit <a href="http://sgv.disko.love">SightGlassVision.com</a>.\r\n \r\n \r\n \r\n <strong>About SightGlass Vision</strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n <em>SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.</em>\r\n \r\n <strong><u> </u></strong>\r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA, FAAO\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-545-1815 or mike@mcdougallpr.com\r\n \r\n -------------------------------------------------\r\n \r\n <a href="#_ednref1" name="_edn1"></a>\r\n \r\n 1.Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 2. Control of myopia using Diffusion Optics Technology™ spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 3. Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 4. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n \r\n \r\n """ +post_date: "2023-09-05 22:30:59" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Reports Positive Four-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenses" +post_type: "press_releases" +slug: "sightglass-vision-reports-positive-four-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses" #__type: null +"_edit_lock": "1726760119:7" +"_edit_last": "1" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": "" +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "4" +"_yoast_wpseo_wordproof_timestamp": "" +"_thumbnail_id": "1229" +"post_date_gmt": "2023-09-05 20:30:59" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-reports-positive-four-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses" +"to_ping": "" +"pinged": "" +"post_modified": "2023-10-24 11:04:42" +"post_modified_gmt": "2023-10-24 09:04:42" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=1228" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 4 => Timber\Post {#2893 +id: 770 +ID: 770 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:27 [ "_edit_lock" => "1692707136:4" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ REFERENCES\r\n \r\n 1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 2 Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 3 Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-07" "_thumbnail_id" => "1111" ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference/" #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n <strong>LOS ALTOS, CALIF., June 6, 2023</strong>—With a goal to continuously improve myopia control adoption and outcomes, SightGlass Vision is presenting a range of new scientific studies and professional education at the 2023 BCLA Clinical Conference. Taking place from June 9-11 in Manchester, England, the event is expected to attract many of the world’s most prominent ocular health experts.\r\n \r\n Three-Year Myopia Control Efficacy of DOTTM Spectacle Lenses in Young Children (Laughton D., et al.) centers on a sub-group six-to-seven-year-olds who participated in the company’s pivotal CYPRESS clinical trial, with investigators noting expectations of highly progressive myopia and a paucity of efficacy data for this age group. After three years, myopia progression among these young children was limited to <1.00 D in 60% of Diffusion Optics TechnologyTM 0.2 spectacle lens wearers compared to 21% of control lens wearers. This data— shared for the first time in Manchester—further supports previously announced safety and efficacy outcomes.\r\n \r\n Reliability of Quality of Vision Questionnaire Results from Children (McParland M., et al.) assessed pediatric application of the Quality of Vision (QoV) questionnaire, which is more commonly used for adult refractive surgery and intraocular lens research. Investigators abbreviated the standard QoV instrument to focus on glare, hazy vision, and halos, then analyzed responses from CYPRESS clinical trial participants and from their parents/guardians across three years. The greater consistency of within-child agreement compared to parent- child response agreement suggests that parents may under-report their children’s experiences, while also affirming that children as young as age six can share meaningful QoV- derived insights to help inform clinical decisions.\r\n \r\n Peripheral Visual Function with DOT Spectacle Lenses for Myopia Control (Aboualizadeh E., et al.) debuts at the BCLA meeting, tapping into the rich CYPRESS data set to review long-term changes in peripheral visual acuity (VA) after three years of Diffusion Optics TechnologyTM spectacle lens wear. Compared to the baseline, peripheral VA improved or remained stable, with no significant differences between the DOT and standard single-vision groups.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n SightGlass Vision has also organized one of eight prominent peer review track sessions at the conference on Saturday: How Do Myopia Management Therapies Work and Does It Matter?, led by global myopia experts Prof. Nicola Logan and Prof. James Wolffsohn. Anticipated high demand for the session requires pre-booking from attendees.\r\n \r\n “We are deeply committed to advancing myopia control, evidenced by our presentations at the BCLA Conference plus recent efficacy, safety, and visual performance data reporting at ARVO in North America and COOC in China. Eye care professionals can confidently prescribe Diffusion Optics TechnologyTM spectacle lenses, knowing the outcomes are supported by extensive science,” said Andrew Sedgwick, CEO of SightGlass Vision.\r\n \r\n Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy,1,2,3 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n For more information, visit SightGlassVision.com\r\n \r\n SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n \r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><strong>Media Contact</strong></p>\r\n <p style="text-align: center;">Mike McDougall, APR, Fellow PRSA,\r\n FAAO McDougall Communications for SightGlass Vision\r\n +1-585-434-2150 or mike@mcdougallpr.com</p>\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_date: "2023-06-06 12:17:31" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Presents New Myopia Control Science and Clinical Insights at 2023 BCLA Conference" +post_type: "press_releases" +slug: "sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference" #__type: null +"_edit_lock": "1692707136:4" +"_edit_last": "1" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": """ REFERENCES\r\n \r\n 1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 2 Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 3 Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "3" +"_yoast_wpseo_wordproof_timestamp": "" +"_wp_old_date": "2023-06-07" +"_thumbnail_id": "1111" +"post_date_gmt": "2023-06-06 10:17:31" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-presents-new-myopia-control-science-and-clinical-insights-at-2023-bcla-conference" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-30 11:40:24" +"post_modified_gmt": "2023-06-30 09:40:24" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=770" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 5 => Timber\Post {#2894 +id: 769 +ID: 769 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:27 [ "_edit_lock" => "1688658306:1" "_edit_last" => "1" "_wp_old_date" => "2023-06-07" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ <div class="layoutArea">\r\n <div class="column">\r\n \r\n REFERENCES\r\n \r\n </div>\r\n </div>\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n 1. Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 2. Laughton D., et al. Calculated age-independent myopic axial length growth in the CYPRESS clinical trial. ARVO 2023 Annual Meeting presentation. 26 April 2023.\r\n \r\n 3. Jones et al. Comparison of ocular component growth curves among refractive error groups in children, Invest Ophthalmol Vis Sci. 2005;46:2317-2327\r\n \r\n 4. Jabeen A., et al. Evaluation of the Lag of accommodation with DOT spectacle lenses. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 5. Gantes-Nuñez, F., et al. Optical Characterization of a Diffusion Optics Technology Ophthalmic Lens Designed for Myopia Control. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 6. MeyerD.,etal.Evaluation of Contrast Sensitivity with Diffusion Optics Technology Lenses. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 7. McParland, M., et al. Myopia progression before, during and after the COVID-19 pandemic in North American children. ARVO 2023 Annual Meeting presentation. 23 April 2023.\r\n \r\n 8. Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 9. Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 10. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S.\r\n \r\n </div>\r\n </div> """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_thumbnail_id" => "1197" ] #___content: null #_permalink: "https://sgv.disko.love/releases/new-sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technologytm-spectacle-lenses/" #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><em>Studies Presented at ARVO 2023 Analyze and Evaluate Multiple Performance Characteristics, Including Positive 42-Month CYPRESS Axial Length and SER Outcomes</em></p>\r\n <strong>LOS ALTOS, CALIF., April 23, 2023</strong> - SightGlass Vision today announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics TechnologyTM spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Meeting in New Orleans.\r\n \r\n Most prominent is the reporting of 42-month data from the company’s pivotal CYPRESS study extension. Results reinforced the safety and efficacy of Diffusion Optics TechnologyTM spectacle lenses in children aged 6–10 at the study’s start.1 The latest investigation re- enrolled 98 participants from the original three-year, double-masked, randomized, multi-site clinical trial to generate six additional months of data. Outcomes again demonstrated statistically significant improvements in axial length (AL) and cycloplegic spherical equivalent refraction (cSER) between the test and control groups.\r\n \r\n Separate work calculated age-independent myopia AL growth to evaluate Diffusion Optics TechnologyTM spectacle lens efficacy.2 Because AL growth occurs even in persistently emmetropic eyes as a child develops and is most rapid before preadolescence, deriving an age-adjusted measure is valuable for clinicians and researchers. Physiological AL growth was determined based on age-matched emmetropic eye growth data from the Orinda Longitudinal Study of Myopia3, then compared to AL growth observed in the original three- year CYPRESS study. Children in the test lens group showed 0.23 mm (73%, p=0.003) less pathological AL change than the control group (test: 0.08 ± 0.06 mm; control: 0.31 ± 0.05 mm).\r\n \r\n “The extensive and rigorous science we are communicating at ARVO 2023 demonstrates the depth of our commitment to advancing myopia control, while also building additional confidence in the efficacy, safety, and overall performance of Diffusion Optics TechnologyTM spectacle lenses,” said Andrew Sedgwick, CEO of SightGlass Vision.\r\n \r\n In addition to the featured CYPRESS presentations, SightGlass Vision and its research partners will display several scientific posters at the meeting. A study from the Centre for Ocular Research & Education (CORE) shows that Diffusion Optics TechnologyTM spectacle lenses have no significant effect on accommodative lag after short-term wear.4 Work from Indiana University suggests that Diffusion Optics TechnologyTM contrast-reducing micro-dots do not limit high quality spatial details and good visual performance5, while another Indiana investigation concludes that wearers are unlikely to notice substantial contrast decreases when looking through the spectacle lens treatment zone.6 A SightGlass team also examined the effect of social restrictions during the COVID-19 pandemic on myopia progression in North American children who participated in the CYPRESS study.7\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to soften contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy1ᣟ2ᣟ8ᣟ9ᣟ10 made its commercial debut in several markets, including China, the Netherlands, and Israel, as well as through preliminary market trials in other countries. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n For more information, visit SightGlassVision.com.\r\n \r\n <strong>About SightGlass Vision</strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics TechnologyTM is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_date: "2023-04-23 12:11:42" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "New SightGlass Vision Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology™ Spectacle Lenses at ARVO 2023" +post_type: "press_releases" +slug: "new-sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technologytm-spectacle-lenses" #__type: null +"_edit_lock": "1688658306:1" +"_edit_last": "1" +"_wp_old_date": "2023-06-07" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": """ <div class="layoutArea">\r\n <div class="column">\r\n \r\n REFERENCES\r\n \r\n </div>\r\n </div>\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n 1. Chalberg T., et al. Control of Myopia Using Diffusion Optics Spectacle Lenses: Efficacy and Safety Study (CYPRESS) 42-month results. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 2. Laughton D., et al. Calculated age-independent myopic axial length growth in the CYPRESS clinical trial. ARVO 2023 Annual Meeting presentation. 26 April 2023.\r\n \r\n 3. Jones et al. Comparison of ocular component growth curves among refractive error groups in children, Invest Ophthalmol Vis Sci. 2005;46:2317-2327\r\n \r\n 4. Jabeen A., et al. Evaluation of the Lag of accommodation with DOT spectacle lenses. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 5. Gantes-Nuñez, F., et al. Optical Characterization of a Diffusion Optics Technology Ophthalmic Lens Designed for Myopia Control. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 6. MeyerD.,etal.Evaluation of Contrast Sensitivity with Diffusion Optics Technology Lenses. ARVO 2023 Annual Meeting presentation. 27 April 2023.\r\n \r\n 7. McParland, M., et al. Myopia progression before, during and after the COVID-19 pandemic in North American children. ARVO 2023 Annual Meeting presentation. 23 April 2023.\r\n \r\n 8. Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 9. Rappon J., et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.\r\n \r\n 10. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S.\r\n \r\n </div>\r\n </div> """ +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "3" +"_yoast_wpseo_wordproof_timestamp": "" +"_thumbnail_id": "1197" +"post_date_gmt": "2023-04-23 10:11:42" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "new-sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technologytm-spectacle-lenses" +"to_ping": "" +"pinged": "" +"post_modified": "2023-07-06 17:17:13" +"post_modified_gmt": "2023-07-06 15:17:13" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=769" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 6 => Timber\Post {#2895 +id: 768 +ID: 768 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:27 [ "_edit_lock" => "1688656425:1" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ REFERENCES\r\n \r\n 1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published. Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 2 Joe Rappon, Jay Neitz, Maureen Neitz, Carol Chung, Thomas Walter Chalberg; Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408\r\n \r\n 3 A 36-month clinical trial demonstrated safety and efficacy for children ages six to 10 at enrolment, significantly reducing both axial length and cycloplegic SER progression versus the control. The study has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, three-arm parallel group clinical trial with diverse subjects reflecting the U.S. population. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n 4 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-42\r\n \r\n 5 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-07" "_thumbnail_id" => "1112" ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology-at-cooc/" #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><em>Companies Present Enhanced Lenses, Key Trials Results and Case Reviews in Collaboration with Top Chinese Eye Care Professionals</em></p>\r\n <strong>LOS ALTOS, CALIF., April 12, 2023</strong>—SightGlass Vision will share its innovative myopia control spectacle lens technology at the International Congress of Ophthalmology and Optometry China (COOC), in partnership with Nikon Lenswear. The conference takes place in Shanghai from April 14-16, 2023, attracting the country’s most prominent eye care clinicians, researchers, and educators.\r\n \r\n Spectacle lenses with SightGlass VisionTM Diffusion Optics TechnologyTM use thousands of micro-dots to softly scatter light to reduce contrast on the retina, a unique mechanism of action to control myopia progression in children. Over the last 18 months, this patent- protected technology with clinically proven efficacy1,2,3 made its commercial debut in several markets, including China. The company operates as a joint venture of CooperCompanies and EssilorLuxottica.\r\n \r\n During COOC, SightGlass Vision and Nikon Lenswear will demonstrate the latest lens iteration, featuring enhanced aesthetics that make the micro-dots less visible during everyday wear. In addition, Marcella McParland and Lucill Wang from the SightGlass Vision Clinical, Medical and Professional Affairs team will present side by side with several ophthalmology key opinion leaders, including Dr. Peter Chen from Shanghai ENT and Dr. Liu Longqian from West China Center of Medical Sciences of Sichuan University, to present multiple case reviews and explain results from its multi-year CYPRESS clinical trial. The company has also begun a separate clinical trial in China.\r\n \r\n “Since our launch with Nikon in China several months ago, momentum has continued to grow,” said Andrew Sedgwick, CEO of SightGlass Vision. “No other country has the depth of understanding and awareness of myopia’s impact on society as China, nor the experience of its clinical community with the disease. Our introduction of new, evidence-based Diffusion Optics TechnologyTM to help reach aneven larger segment of children has been widely embraced—something we expect to see first-hand\r\n \r\n at COOC.”\r\n \r\n The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly five billion people—half the world’s population—will be myopic by 2050. 4 Uncorrected myopia is the leading cause of visual impairment in children. Over time, its progression may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia5.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n In addition to China, spectacle lenses with Diffusion Optics Technology are currently available in the Netherlands and Israel, as well as through preliminary market trials in other countries. For more information, visit SightGlassVision.com.\r\n \r\n For more information, visit SightGlassVision.com.\r\n \r\n About SightGlass Vision\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics TechnologyTM is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n SightGlass VisionTM Diffusion Optics TechnologyTM spectacle lenses are not available for sale in the United States.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n \r\n \r\n \r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><strong>Media Contact</strong></p>\r\n <p style="text-align: center;">Mike McDougall, APR, Fellow PRSA,\r\n FAAO McDougall Communications for SightGlass Vision\r\n +1-585-434-2150 or mike@mcdougallpr.com</p>\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_date: "2023-04-12 12:11:07" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Highlights New Myopia Control Spectacle Lens Technology at COOC 2023" +post_type: "press_releases" +slug: "sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology-at-cooc" #__type: null +"_edit_lock": "1688656425:1" +"_edit_last": "1" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": """ REFERENCES\r\n \r\n 1 Control of myopia using Diffusion Optics TechnologyTM spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). British Journal of Ophthalmology Published. Online First: 01 September 2022. DOI: 10.1136/bjo-2021-321005\r\n \r\n 2 Joe Rappon, Jay Neitz, Maureen Neitz, Carol Chung, Thomas Walter Chalberg; Two-year effectiveness of a novel myopia management spectacle lens with full-time WEARERS. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408\r\n \r\n 3 A 36-month clinical trial demonstrated safety and efficacy for children ages six to 10 at enrolment, significantly reducing both axial length and cycloplegic SER progression versus the control. The study has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, three-arm parallel group clinical trial with diverse subjects reflecting the U.S. population. Laughton, D et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. 2022 American Academy of Optometry annual meeting. 27 Oct 2022.\r\n \r\n 4 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-42\r\n \r\n 5 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "3" +"_yoast_wpseo_wordproof_timestamp": "" +"_wp_old_date": "2023-06-07" +"_thumbnail_id": "1112" +"post_date_gmt": "2023-04-12 10:11:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-highlights-new-myopia-control-spectacle-lens-technology-at-cooc" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-30 11:41:11" +"post_modified_gmt": "2023-06-30 09:41:11" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=768" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 7 => Timber\Post {#2896 +id: 418 +ID: 418 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:27 [ "_edit_last" => "2" "_edit_lock" => "1688656426:1" "_thumbnail_id" => "1002" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ REFERENCES\r\n \r\n 1 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 23(5):1036-42\r\n \r\n 2 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_yoast_wpseo_content_score" => "30" "_wp_old_date" => array:2 [ 0 => "2023-05-03" 1 => "2023-04-12" ] ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-unveils-topline-data-from-cypress-pivotal-study-of-novel-eyeglasses/" #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: """ <div class="page" title="Page 1">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><em>Diffusion Optics TechnologyTM Effective for Young Children;</em>\r\n <em>Complete Results Presented at 2022 American Academy of Optometry Meeting</em></p>\r\n <strong>LOS ALTOS, CALIF., October 24, 2022</strong>—Analysis of 36-month data from the pivotal CYPRESS myopia control clinical trial has demonstrated the safety and efficacy of SightGlass VisionTM spectacle lenses with Diffusion Optics TechnologyTM for children ages six to 10 years at enrollment. The intervention significantly reduced both axial length and cycloplegic SER progression versus the control.\r\n \r\n Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years (Laughton, D et al) will be presented at the 2022 American Academy of Optometry annual meeting in San Diego on Thursday, October 27.*\r\n \r\n In addition to illustrating myopia control efficacy, 36-month data showed low device-related adverse event rates. No serious adverse events were reported. Visual performance for distance and near was excellent (20/20 or better) and remained stable, and low contrast visual acuity was similar to control. While the lens proved beneficial at all ages, the slowing of myopia progression among children ages six to seven years at the initiation of treatment is of particular note.\r\n \r\n “There are currently no other interventions with this degree of demonstrated efficacy for six- and seven-year-old children, even though more severe adult myopia is generally linked to earlier onset,” said Andrew Sedgwick, CEO of SightGlass Vision. “We purposefully enrolled a subset of younger children to examine this gap in myopia control research and treatment options. With its unique mechanism of action, our Diffusion Optics Technology is a new approach and represents a first line of defense for young myopes.”\r\n \r\n Lenses that incorporate SightGlass Vision Diffusion Optics Technology use thousands of micro- dots that softly scatter light to reduce contrast on the retina and are designed to reduce myopia progression in children.\r\n \r\n CYPRESS has been recognized for its rigor, designed as a prospective, randomized, controlled, subject and observer masked, multi-site, diverse study population reflecting the U.S. population, three-arm parallel group clinical trial. During the paper presentation, researchers will also share early observations from the CYPRESS extension study, which tracks clinical results beyond the 36-month mark.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n \r\n IThe last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly five billion people—half the world’s population—will be myopic by 2050.1 Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased riskof developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.2\r\n \r\n DOT 0.2 spectacle lenses are not approved in the United States. ###\r\n \r\n *Academy attendees can attend the Safety and Efficacy of a Novel Spectacle Lens for Myopia\r\n Control Over Three Years paper presentation at 3:15 p.m. PT on Thursday, Oct. 27 in the San Diego Convention Center, Upper Level, Room 29CD.\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div>\r\n \r\n \r\n \r\n <div class="page" title="Page 2">\r\n <div class="section">\r\n <div class="layoutArea">\r\n <div class="column">\r\n <p style="text-align: center;"><strong>Media Contact</strong></p>\r\n <p style="text-align: center;">Mike McDougall, APR, Fellow PRSA, FAAO\r\n McDougall Communications for SightGlass Vision\r\n +1-585-434-2150 or mike@mcdougallpr.com</p>\r\n \r\n </div>\r\n </div>\r\n </div>\r\n </div> """ +post_date: "2022-10-24 11:05:40" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Spectacles Reduce Myopia Progression in Children, According to Three Year Clinical Study Data - AAO 2023" +post_type: "press_releases" +slug: "sightglass-vision-unveils-topline-data-from-cypress-pivotal-study-of-novel-eyeglasses" #__type: null +"_edit_last": "2" +"_edit_lock": "1688656426:1" +"_thumbnail_id": "1002" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": """ REFERENCES\r\n \r\n 1 Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 23(5):1036-42\r\n \r\n 2 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363\r\n \r\n \r\n \r\n Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_estimated-reading-time-minutes": "3" +"_yoast_wpseo_wordproof_timestamp": "" +"_yoast_wpseo_content_score": "30" +"_wp_old_date": array:2 [ 0 => "2023-05-03" 1 => "2023-04-12" ] +"post_date_gmt": "2022-10-24 09:05:40" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-unveils-topline-data-from-cypress-pivotal-study-of-novel-eyeglasses" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-27 09:38:54" +"post_modified_gmt": "2023-06-27 07:38:54" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=418" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 8 => Timber\Post {#2897 +id: 914 +ID: 914 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:27 [ "_edit_lock" => "1688656426:1" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_thumbnail_id" => "1110" "_wp_old_date" => "2023-06-23" ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-celebrates-major-milestones-at-imc-2022/" #_next: [] #_prev: [] #_css_class: null +post_author: "2" +post_content: """ <b><span data-contrast="auto">LOS ALTOS, CALIF., 1 September 2022</span></b><span data-contrast="auto">—When the 18</span><span data-contrast="auto">th</span><span data-contrast="auto"> International Myopia Conference (IMC) opens in Rotterdam next week, it will mark a series of milestones for one of the most promising technology companies in the category. For the first time, SightGlass Vision will exhibit at the meeting, in addition to presenting additional data and insights related to its Diffusion Optics Technology</span><span data-contrast="auto">™</span><span data-contrast="auto"> as well as CYPRESS clinical trial, including preliminary three-year results findings.</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-ccp-props="{"335551550":6,"335551620":6}"> </span><span data-contrast="auto">Spectacle lenses using patent-protected SightGlass Vision</span><span data-contrast="auto">™</span><span data-contrast="auto"> Diffusion Optics Technology</span><span data-contrast="auto">™️</span><span data-contrast="auto"> incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">“SightGlass Vision is now fully operational. Our entire leadership group is in place, and we are making good progress on commercial launches in markets such as China, Israel, and the Netherlands, with more to come,” said Andrew Sedgwick, the company’s CEO. “Enthusiastic reaction to our latest data analysis on younger children enrolled in CYPRESS, which suggests we have a promising approach to myopia control for children as early as age six, is inspiring—to our team and the eye care profession. We’re looking forward to discussing those findings in even greater depth at the IMC.” </span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">Younger ages are of particular interest to eye care professionals and researchers, since myopia progresses fastest in the youngest children.¹,²</span><span data-contrast="auto"> Because progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health. </span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">On Sunday, 4 September, at 12:40 pm CET, SightGlass Vision will host an all-attendee luncheon session on contrast theory and the Science behind Diffusion Optics Technology™. </span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">Its researchers will also participate in the Optical Interventions session on Tuesday 6 September at 8:45 am CET, presenting </span><i><span data-contrast="auto">The Visual Performance with N</span></i><i><span data-contrast="auto">ovel Spectacle Lenses for Myopia Control</span></i><span data-contrast="auto"> (Laughton D, et al.). After three years, children wearing the lenses with Diffusion Optics Technology</span><span data-contrast="auto">™️</span><span data-contrast="auto"> demonstrated significantly less myopia progression than the control group. The novel spectacle lenses provided good all-round visual performance and were well tolerated for the study duration.</span><span data-contrast="auto">³</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">The company is a gold sponsor of the 2022 IMC, joining other global organizations in addressing the global myopia epidemic.</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n \r\n <span data-contrast="auto">The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people—half the world’s population—will be myopic by 2050.₄</span><span data-contrast="auto"> Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁵</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span>\r\n <p style="text-align: center;"># # #</p>\r\n <strong><u>About SightGlass Vision</u></strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-434-2150 or mike@mcdougallpr.com\r\n \r\n \r\n <ol>\r\n \t<li>Hyman L, et al. <em>Relationship of Age, Sex, and Ethnicity with Myopia Progression and Axial Elongation in the Correction of Myopia Evaluation Trial</em>. Archives of Ophthalmology. 2005;123(7):977 987.</li>\r\n \t<li>Verkicharla PK, Kammari P, Das AV. <em>Myopia progression varies with age and severity of myopia</em>. PLOS ONE. 2020;15(11):e0241759.</li>\r\n \t<li>SGV data on file 2022. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 3-Year Final Report (n = 256, 14 North American sites).</li>\r\n \t<li>Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. <em>Ophthalmology</em> 2016. 123(5):1036-42</li>\r\n \t<li>Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. <em>JAMA Ophthalmol</em>. 2016;134:1355-1363</li>\r\n </ol> """ +post_date: "2022-09-01 10:27:38" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Celebrates Major Milestones at IMC 2022" +post_type: "press_releases" +slug: "sightglass-vision-celebrates-major-milestones-at-imc-2022" #__type: null +"_edit_lock": "1688656426:1" +"_edit_last": "1" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "3" +"_yoast_wpseo_wordproof_timestamp": "" +"_thumbnail_id": "1110" +"_wp_old_date": "2023-06-23" +"post_date_gmt": "2022-09-01 08:27:38" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-celebrates-major-milestones-at-imc-2022" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-30 11:41:38" +"post_modified_gmt": "2023-06-30 09:41:38" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=914" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 9 => Timber\Post {#2898 +id: 916 +ID: 916 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:27 [ "_edit_lock" => "1688658307:1" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "3" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-23" "_thumbnail_id" => "1197" ] #___content: null #_permalink: "https://sgv.disko.love/releases/sightglass-vision-spectacles-control-myopia-progression-for-6-and-7-year-olds-according-to-new-data-analysis-ncc2022/" #_next: [] #_prev: [] #_css_class: null +post_author: "2" +post_content: """ <strong>PALO ALTO, CALIF., June 23, 2022</strong>—Analysis of 24-month interim data from the pivotal CYPRESS clinical trial is offering increased hope for controlling myopia progression among young children. Spectacles that use SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™</sup> were shown to significantly reduce both axial length (mean absolute reduction = 0.27 mm) and cycloplegic SER progression (mean absolute reduction = 0.77 D) in six- and seven-year-old children versus the control.*\r\n \r\n <em>Two Year Effectiveness of a Novel Myopia Management Spectacle Lens in Young Myopes </em>(Rappon J, Neitz J, Neitz M, Chalberg T) will be presented for the first time at the 2022 Dutch Contact Lens Congress (NCC), which begins next week in Eindhoven, The Netherlands.\r\n \r\n The focus on age is of particular interest to eye care professionals and researchers, as myopia progresses fastest in the youngest children.<sup>¹,²</sup> Since progression cannot be reversed, immediate intervention to slow or even stop progression is critical to a child’s short-term vision and long-term ocular health.\r\n \r\n “Young myopes can be difficult to manage for many reasons. Parents and eye care professionals have traditionally had a limited number of myopia control solutions for younger children,” said Andrew Sedgwick, CEO of SightGlass Vision. “Our latest analysis suggests that spectacles enabled with SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™</sup> offer a promising new approach to myopia control for six- and seven-year-olds.”\r\n \r\n Study investigators enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada—a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D, with nearly a third of them being six or seven years old. With a mean age of 8.1 years at screening, the entire CYPRESS cohort is younger than children in many other well-known myopia management studies across various interventions. The trial is now in its third year.\r\n \r\n Spectacle lenses using patent-protected SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™️</sup> incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.\r\n \r\n The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people—half the world’s population—will be myopic by 2050.³ Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁴\r\n \r\n \r\n <p style="text-align: center;"># # #</p>\r\n <strong><u>About SightGlass Vision</u></strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-434-2150 or mike@mcdougallpr.com\r\n \r\n <a href="#_ednref1" name="_edn1">[1]</a> Hyman L, et al. <em>Relationship of Age, Sex, and Ethnicity with Myopia Progression and Axial Elongation in the Correction of Myopia Evaluation Trial</em>. Archives of Ophthalmology. 2005;123(7):977 987.\r\n \r\n <a href="#_ednref2" name="_edn2">[2]</a> Verkicharla PK, Kammari P, Das AV. <em>Myopia progression varies with age and severity of myopia</em>. PLOS ONE. 2020;15(11):e0241759.\r\n \r\n <a href="#_ednref3" name="_edn3">[3]</a> Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. <em>Ophthalmology</em> 2016. 123(5):1036-42\r\n \r\n <a href="#_ednref4" name="_edn4">[4]</a> Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. <em>JAMA Ophthalmol</em>. 2016;134:1355-1363 """ +post_date: "2022-06-23 10:35:45" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "SightGlass Vision Spectacles Control Myopia Progression for 6- and 7-Year-Olds, According to New Data Analysis - NCC2022" +post_type: "press_releases" +slug: "sightglass-vision-spectacles-control-myopia-progression-for-6-and-7-year-olds-according-to-new-data-analysis-ncc2022" #__type: null +"_edit_lock": "1688658307:1" +"_edit_last": "1" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "3" +"_yoast_wpseo_wordproof_timestamp": "" +"_wp_old_date": "2023-06-23" +"_thumbnail_id": "1197" +"post_date_gmt": "2022-06-23 08:35:45" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "sightglass-vision-spectacles-control-myopia-progression-for-6-and-7-year-olds-according-to-new-data-analysis-ncc2022" +"to_ping": "" +"pinged": "" +"post_modified": "2023-07-06 17:18:54" +"post_modified_gmt": "2023-07-06 15:18:54" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=916" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } 10 => Timber\Post {#2899 +id: 915 +ID: 915 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:27 [ "_edit_lock" => "1691671589:4" "_edit_last" => "1" "video_poster" => "" "_video_poster" => "field_644bbb0d9ed45" "video_file" => "" "_video_file" => "field_644bbb169ed46" "video" => "" "_video" => "field_644bbaea9ed44" "push_link_image" => "" "_push_link_image" => "field_644bbb379ed48" "push_link_texte" => "" "_push_link_texte" => "field_644bbb409ed49" "push_link_link" => "" "_push_link_link" => "field_644bbb469ed4a" "push_link" => "" "_push_link" => "field_644bbb259ed47" "related_type" => "auto" "_related_type" => "field_644bbb639ed4c" "related" => "" "_related" => "field_644bbb559ed4b" "mentions" => """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ "_mentions" => "field_644bbbb29ed4e" "_yoast_wpseo_content_score" => "30" "_yoast_wpseo_estimated-reading-time-minutes" => "4" "_yoast_wpseo_wordproof_timestamp" => "" "_wp_old_date" => "2023-06-23" "_thumbnail_id" => "1197" ] #___content: null #_permalink: "https://sgv.disko.love/releases/arvo-2022-24-month-data-demonstrates-myopia-control-efficacy-for-sightglass-vision-spectacle-lenses/" #_next: [] #_prev: [] #_css_class: null +post_author: "2" +post_content: """ <strong>PALO ALTO, CALIF., May 2, 2022</strong>—Spectacles that use SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™</sup> have demonstrated efficacy in slowing the progression of myopia in children,¹ based on 24-month interim data from its pivotal clinical trial data presented this week at ARVO 2022.\r\n \r\n <em>Two Year Effectiveness of a Novel Myopia Management Spectacle Lens with Full Time Wearers </em>(Rappon J, Neitz J, Neitz M , Chung C, Chalberg T) is a featured presentation at the annual conference, which is attended by thousands of the world’s most respected ophthalmology, optometry, and vision science researchers.\r\n \r\n An analysis of full-time wearers—children ages 6-10 at initiation whose parents reported that they did not remove the study spectacles for near vision activities —showed statistically significant improvements between groups using Diffusion Optics Technology<sup>™</sup> lenses and the control. Axial length exhibited a 0.21 mm difference, and the spherical equivalent refraction difference was 0.52 D.\r\n \r\n Study investigators enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada—a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D. The CYPRESS trial is now in its third year.\r\n \r\n With a mean age of 8.1 years at screening, the CYPRESS cohort is younger than children in other well-known myopia management studies.<sup>²,³,⁴</sup> Given the higher likelihood of spectacles-based interventions for younger children, this study parameter should help build confidence in prescribers and families alike. Additional analysis of younger wearers will be presented at NCC 2022 this June.\r\n \r\n Spectacle lenses using patent-protected SightGlass Vision<sup>™</sup> Diffusion Optics Technology<sup>™️</sup> incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children.\r\n \r\n “With their unique mechanism of action, Diffusion Optics Technology<sup>™</sup> spectacle lenses represent a promising new approach to myopia control,” said Andrew Sedgwick, CEO of SightGlass Vision. “We’re enthusiastic about sharing more detail from the two-year interim results, which will further support our development efforts and ongoing commercialization activities in select markets.”\r\n \r\n The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people – half the world’s population – will be myopic by 2050.⁵ Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.⁶\r\n <p style="text-align: center;"><u>###</u></p>\r\n <strong><u>About SightGlass Vision</u></strong>\r\n \r\n SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of micro-dots that softly scatter light to reduce contrast on the retina—a method intended to reduce myopia progression in children. The treatment is currently in year three of a pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.\r\n \r\n \r\n \r\n <strong><u>Media Contact</u></strong>\r\n \r\n Mike McDougall, APR, Fellow PRSA\r\n \r\n McDougall Communications for SightGlass Vision\r\n \r\n +1-585-434-2150 or mike@mcdougallpr.com\r\n \r\n \r\n <ol>\r\n \t<li>Spectacles with SightGlass Vision Diffusion Optics Technology™ are not approved for sale within the United States.</li>\r\n \t<li>GwiazdaJ, Hyman L, Hussein M, et al. A Randomized Clinical Trial of Progressive Addition Lenses versus Single Vision Lenses on the Progression of Myopia in Children. <em>Invest OphthalmolVis Sci</em>. 2003;44(4):1492.</li>\r\n \t<li>Walline JJ, GaumeGiannoni A, Sinnott LT, et al. A Randomized Trial of Soft Multifocal Contact Lenses for Myopia Control: Baseline Data and Methods. <em>Optometry and Vision Science</em>. 2017;94(9):856-866.</li>\r\n \t<li>Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study. <em>Ophthalmology</em>. 2019;126(1):113-124.</li>\r\n \t<li>Holden et al. Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. <em>Ophthalmology</em> 2016. 123(5):1036-42</li>\r\n \t<li>Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. <em>JAMA Ophthalmol</em>. 2016;134:1355-1363</li>\r\n </ol> """ +post_date: "2022-05-02 10:32:24" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "ARVO 2022: 24-Month Data Demonstrates Myopia Control Efficacy for SightGlass Vision Spectacle Lenses" +post_type: "press_releases" +slug: "arvo-2022-24-month-data-demonstrates-myopia-control-efficacy-for-sightglass-vision-spectacle-lenses" #__type: null +"_edit_lock": "1691671589:4" +"_edit_last": "1" +"video_poster": "" +"_video_poster": "field_644bbb0d9ed45" +"video_file": "" +"_video_file": "field_644bbb169ed46" +"_video": "field_644bbaea9ed44" +"push_link_image": "" +"_push_link_image": "field_644bbb379ed48" +"push_link_texte": "" +"_push_link_texte": "field_644bbb409ed49" +"push_link_link": "" +"_push_link_link": "field_644bbb469ed4a" +"push_link": "" +"_push_link": "field_644bbb259ed47" +"related_type": "auto" +"_related_type": "field_644bbb639ed4c" +"related": "" +"_related": "field_644bbb559ed4b" +"mentions": """ Please note that our products are not available for sale or distribution in every country in the world.\r\n Our products are not available for sale in the U.S. """ +"_mentions": "field_644bbbb29ed4e" +"_yoast_wpseo_content_score": "30" +"_yoast_wpseo_estimated-reading-time-minutes": "4" +"_yoast_wpseo_wordproof_timestamp": "" +"_wp_old_date": "2023-06-23" +"_thumbnail_id": "1197" +"post_date_gmt": "2022-05-02 08:32:24" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "arvo-2022-24-month-data-demonstrates-myopia-control-efficacy-for-sightglass-vision-spectacle-lenses" +"to_ping": "" +"pinged": "" +"post_modified": "2023-07-06 17:19:01" +"post_modified_gmt": "2023-07-06 15:19:01" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?post_type=press_releases&p=915" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } ] : false : false : "Timber\PostsIterator" } ]
TimberPost
ID:
419
post_type:
page
slug:
press-release
post_name:
press-release
post_title:
Press Release
^ array:49 [ "id" => 419 "ID" => 419 "object_type" => "post" "ImageClass" => "Timber\Image" "PostClass" => "Timber\Post" "TermClass" => "Timber\Term" "custom" => array:11 [ "_edit_last" => "1" "_wp_page_template" => "press" "_yoast_wpseo_estimated-reading-time-minutes" => "0" "_yoast_wpseo_wordproof_timestamp" => "" "references" => "" "_references" => "field_644943738e91a" "_edit_lock" => "1692709771:4" "featured_pages" => array:1 [ 0 => "432" ] "_featured_pages" => "field_64522e2a4e468" "_yoast_wpseo_title" => "%%sitename%% %%sep%% %%title%%" "_yoast_wpseo_metadesc" => "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." ] "\x00*\x00___content" => null "\x00*\x00_permalink" => null "\x00*\x00_next" => [] "\x00*\x00_prev" => [] "\x00*\x00_css_class" => null "post_author" => "1" "post_content" => "" "post_date" => "2023-05-03 11:09:45" "post_excerpt" => "" "post_parent" => 0 "post_status" => "publish" "post_title" => "Press Release" "post_type" => "page" "slug" => "press-release" "\x00*\x00__type" => null "_edit_last" => "1" "_wp_page_template" => "press" "_yoast_wpseo_estimated-reading-time-minutes" => "0" "_yoast_wpseo_wordproof_timestamp" => "" "references" => "" "_references" => "field_644943738e91a" "_edit_lock" => "1692709771:4" "featured_pages" => array:1 [ 0 => "432" ] "_featured_pages" => "field_64522e2a4e468" "_yoast_wpseo_title" => "%%sitename%% %%sep%% %%title%%" "_yoast_wpseo_metadesc" => "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." "post_date_gmt" => "2023-05-03 09:09:45" "comment_status" => "closed" "ping_status" => "closed" "post_password" => "" "post_name" => "press-release" "to_ping" => "" "pinged" => "" "post_modified" => "2023-06-27 16:52:08" "post_modified_gmt" => "2023-06-27 14:52:08" "post_content_filtered" => "" "guid" => "https://www.sightglassvision.com/?page_id=419" "menu_order" => 0 "post_mime_type" => "" "comment_count" => "0" "filter" => "raw" "status" => "publish" ]
Timber Context
Base Context
^ array:10 [ "http_host" => "https://sgv.disko.love" "wp_title" => "SightGlass Vision | Press Release" "body_class" => "page-template page-template-press page page-id-419" "site" => Timber\Site {#2863 +id: null +ID: null +object_type: null +admin_email: "tech@disko.fr" +blogname: null +charset: "UTF-8" +description: "" +language: "en_US" +multisite: false +name: "SightGlass Vision" +pingback_url: "https://sgv.disko.love/xmlrpc.php" +siteurl: null +theme: Timber\Theme {#2868 +id: null +ID: null +object_type: null +name: "Yagami - Adveris" +version: "" +parent: false +parent_slug: null +slug: "yagami-adveris" +uri: "https://sgv.disko.love/wp-content/themes/yagami-adveris" -theme: WP_Theme {#2869 +update: false -theme_root: "/opt/bitnami/wordpress/wp-content/themes" -headers: array:14 [ "Name" => "Yagami - Adveris" "ThemeURI" => "" "Description" => "Custom starter to build wordpress theme from scratch" "Author" => "Adveris" "AuthorURI" => "https://www.adveris.fr/" "Version" => "" "Template" => "" "Status" => "" "Tags" => "yagami, blank" "TextDomain" => "Yagami" "DomainPath" => "" "RequiresWP" => "" "RequiresPHP" => "" "UpdateURI" => "" ] -headers_sanitized: array:2 [ "Name" => "Yagami - Adveris" "Version" => "" ] -block_theme: false -name_translated: null -errors: null -stylesheet: "yagami-adveris" -template: "yagami-adveris" -parent: null -theme_root_uri: "https://sgv.disko.love/wp-content/themes" -textdomain_loaded: null -cache_hash: "a5902282552af3f00ade54f56095ec22" -block_template_folders: array:2 [ "wp_template" => "templates" "wp_template_part" => "parts" ] -default_template_folders: array:2 [ "wp_template" => "templates" "wp_template_part" => "parts" ] } } +title: "SightGlass Vision" +url: "https://sgv.disko.love" +home_url: "https://sgv.disko.love" +site_url: "https://sgv.disko.love" +rdf: "https://sgv.disko.love/feed/rdf/" +rss: "https://sgv.disko.love/feed/rss/" +rss2: "https://sgv.disko.love/feed/" +atom: "https://sgv.disko.love/feed/atom/" +"pingback": "https://sgv.disko.love/xmlrpc.php" } "request" => Timber\Request {#2854 +id: null +ID: null +object_type: null +post: [] +get: [] } "user" => false "theme" => Timber\Theme {#2868} "posts" => Timber\PostQuery {#2870 +found_posts: 1 : 1 #userQuery: false #queryIterator: Timber\QueryIterator {#2871 -_query: WP_Query {#1108 +query: array:2 [ "page" => "" "pagename" => "press-release" ] +query_vars: array:66 [ "page" => 0 "pagename" => "press-release" "error" => "" "m" => "" "p" => 0 "post_parent" => "" "subpost" => "" "subpost_id" => "" "attachment" => "" "attachment_id" => 0 "name" => "press-release" "page_id" => 0 "second" => "" "minute" => "" "hour" => "" "day" => 0 "monthnum" => 0 "year" => 0 "w" => 0 "category_name" => "" "tag" => "" "cat" => "" "tag_id" => "" "author" => "" "author_name" => "" "feed" => "" "tb" => "" "paged" => 0 "meta_key" => "" "meta_value" => "" "preview" => "" "s" => "" "sentence" => "" "title" => "" "fields" => "" "menu_order" => "" "embed" => "" "category__in" => [] "category__not_in" => [] "category__and" => [] "post__in" => [] "post__not_in" => [] "post_name__in" => [] "tag__in" => [] "tag__not_in" => [] "tag__and" => [] "tag_slug__in" => [] "tag_slug__and" => [] "post_parent__in" => [] "post_parent__not_in" => [] "author__in" => [] "author__not_in" => [] "search_columns" => [] "ignore_sticky_posts" => false "suppress_filters" => false "cache_results" => true "update_post_term_cache" => true "update_menu_item_cache" => false "lazy_load_term_meta" => true "update_post_meta_cache" => true "post_type" => "" "posts_per_page" => 10 "nopaging" => false "comments_per_page" => "50" "no_found_rows" => false "order" => "DESC" ] +tax_query: null +meta_query: WP_Meta_Query {#2539 +queries: [] +relation: null +meta_table: null +meta_id_column: null +primary_table: null +primary_id_column: null #table_aliases: [] #clauses: [] #has_or_relation: false } +date_query: false +queried_object: WP_Post {#2536 +ID: 419 +post_author: "1" +post_date: "2023-05-03 11:09:45" +post_date_gmt: "2023-05-03 09:09:45" +post_content: "" +post_title: "Press Release" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "press-release" +to_ping: "" +pinged: "" +post_modified: "2023-06-27 16:52:08" +post_modified_gmt: "2023-06-27 14:52:08" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?page_id=419" +menu_order: 0 +post_type: "page" +post_mime_type: "" +comment_count: "0" +filter: "raw" } +queried_object_id: 419 +request: """ SELECT wp_posts.*\n \t\t\t\t\t FROM wp_posts \n \t\t\t\t\t WHERE 1=1 AND (wp_posts.ID = '419') AND wp_posts.post_type = 'page'\n \t\t\t\t\t \n \t\t\t\t\t ORDER BY wp_posts.post_date DESC\n \t\t\t\t\t """ +posts: & array:1 [ 0 => WP_Post {#2540 +ID: 419 +post_author: "1" +post_date: "2023-05-03 11:09:45" +post_date_gmt: "2023-05-03 09:09:45" +post_content: "" +post_title: "Press Release" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "press-release" +to_ping: "" +pinged: "" +post_modified: "2023-06-27 16:52:08" +post_modified_gmt: "2023-06-27 14:52:08" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?page_id=419" +menu_order: 0 +post_type: "page" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 419 +"slug": "press-release" +"custom": array:11 [ "_edit_last" => "1" "_wp_page_template" => "press" "_yoast_wpseo_estimated-reading-time-minutes" => "0" "_yoast_wpseo_wordproof_timestamp" => "" "references" => "" "_references" => "field_644943738e91a" "_edit_lock" => "1692709771:4" "featured_pages" => array:1 [ 0 => "432" ] "_featured_pages" => "field_64522e2a4e468" "_yoast_wpseo_title" => "%%sitename%% %%sep%% %%title%%" "_yoast_wpseo_metadesc" => "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." ] } ] +post_count: 1 +current_post: -1 +before_loop: true +in_the_loop: false +post: WP_Post {#2540} +comment_count: 0 +current_comment: -1 +found_posts: 1 +max_num_pages: 0 +max_num_comment_pages: 0 +is_single: false +is_preview: false +is_page: true +is_archive: false +is_date: false +is_year: false +is_month: false +is_day: false +is_time: false +is_author: false +is_category: false +is_tag: false +is_tax: false +is_search: false +is_feed: false +is_comment_feed: false +is_trackback: false +is_home: false +is_privacy_policy: false +is_404: false +is_embed: false +is_paged: false +is_admin: false +is_attachment: false +is_singular: true +is_robots: false +is_favicon: false +is_posts_page: false +is_post_type_archive: false -query_vars_hash: "8b3e11791d3e223569b8f01969a5cc07" -query_vars_changed: false +thumbnails_cached: false #allow_query_attachment_by_filename: false -stopwords: null -compat_fields: array:2 [ 0 => "query_vars_hash" 1 => "query_vars_changed" ] -compat_methods: array:2 [ 0 => "init_query_flags" 1 => "parse_tax_query" ] } -_posts_class: "\Timber\Post" } #pagination: null -storage: array:1 [ 0 => Timber\Post {#2873 +id: 419 +ID: 419 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:11 [ "_edit_last" => "1" "_wp_page_template" => "press" "_yoast_wpseo_estimated-reading-time-minutes" => "0" "_yoast_wpseo_wordproof_timestamp" => "" "references" => "" "_references" => "field_644943738e91a" "_edit_lock" => "1692709771:4" "featured_pages" => array:1 [ 0 => "432" ] "_featured_pages" => "field_64522e2a4e468" "_yoast_wpseo_title" => "%%sitename%% %%sep%% %%title%%" "_yoast_wpseo_metadesc" => "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." ] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: "" +post_date: "2023-05-03 11:09:45" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "Press Release" +post_type: "page" +slug: "press-release" #__type: null +"_edit_last": "1" +"_wp_page_template": "press" +"_yoast_wpseo_estimated-reading-time-minutes": "0" +"_yoast_wpseo_wordproof_timestamp": "" +"references": "" +"_references": "field_644943738e91a" +"_edit_lock": "1692709771:4" +"featured_pages": array:1 [ 0 => "432" ] +"_featured_pages": "field_64522e2a4e468" +"_yoast_wpseo_title": "%%sitename%% %%sep%% %%title%%" +"_yoast_wpseo_metadesc": "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." +"post_date_gmt": "2023-05-03 09:09:45" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "press-release" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-27 16:52:08" +"post_modified_gmt": "2023-06-27 14:52:08" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?page_id=419" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } ] : false : false : "Timber\PostsIterator" } "wp_head" => Timber\FunctionWrapper {#2872 -_class: null -_function: "wp_head" -_args: [] -_use_ob: false } "wp_footer" => Timber\FunctionWrapper {#2875 -_class: null -_function: "wp_footer" -_args: [] -_use_ob: false } ]
Custom Context
^ array:28 [ "timber" => Managers\TimberManager {#1141 -configuration: array:4 [ "timber" => array:2 [ "views_location" => "/views" "links" => array:1 [ "archives" => array:1 [ "news" => "post" ] ] ] "wordpress" => array:5 [ "show_admin_bar" => false "clear_head_for_yoast" => true "theme_supports" => array:5 [ 0 => "title-tag" 1 => "post-formats" 2 => "post-thumbnails" 3 => "menus" 4 => array:2 [ "support" => "html5" "arg" => array:5 [ …5] ] ] "menus" => array:3 [ "primary" => "Menu Principal" "secondary" => "Menu Secondaire" "links" => "Menu Liens" ] "remove_action" => array:1 [ "wp_head" => "wp_generator" ] ] "acf" => array:2 [ "google_map_api_key" => "AIzaSyDGF98psyVSiyiVhFovqfhMDrGJ-Ls2Uoc" "options" => array:1 [ "general_options" => array:2 [ "page" => array:4 [ …4] "sub_menus" => array:2 [ …2] ] ] ] "polylang" => array:1 [ "polylang_strings" => array:10 [ 0 => array:1 [ "yagami_demo_title" => "Site de démonstration<br/> du starter thème Yagami Adveris\n" ] 1 => array:1 [ "yagami_demo_content" => "Ce site Wordpress de démonstration présente le starter Adveris avec le thème "Yagami Adveris". Ce starter installe nativement les modules clés pour un site Wordpress optimisé. Le thème est ensuite adapté au design 100% sur-mesure créé par le studio créatif de l'agence.\n" ] 2 => array:1 [ "error_404_message" => "Cette page n'existe pas\n" ] 3 => array:1 [ "back_to_home" => "Retour à l'accueil\n" ] 4 => array:1 [ "news" => "Article\n" ] 5 => array:1 [ "all_news" => "All articles" ] 6 => array:1 [ "others_news" => "Other articles" ] 7 => array:1 [ "published_on" => "Published on" ] 8 => array:1 [ "play_video" => "Play video" ] 9 => array:1 [ "press_release" => "Press Release" ] ] ] ] } "services" => Services\TimberService {#2628} "src" => "https://sgv.disko.love/wp-content/themes/yagami-adveris/web/src" "src_rel" => "/wp-content/themes/yagami-adveris/web/src" "img" => "https://sgv.disko.love/wp-content/themes/yagami-adveris/web/src/img" "img_rel" => "/wp-content/themes/yagami-adveris/web/src/img" "img_path" => "/opt/bitnami/wordpress/wp-content/themes/yagami-adveris/web/src/img" "dist" => "https://sgv.disko.love/wp-content/themes/yagami-adveris/web/dist" "dist_rel" => "/wp-content/themes/yagami-adveris/web/dist" "options" => array:9 [ "body_bottom_script" => "" "body_top_script" => "" "cookies_list" => """ <!-- CookiePro Cookies List start -->\r\n <div id="ot-sdk-cookie-policy"></div>\r\n <!-- CookiePro Cookies List end --> """ "cookies_script" => """ <!-- CookiePro Cookies Consent Notice start for sigthglassvision.com -->\r\n <script src="https://cookie-cdn.cookiepro.com/scripttemplates/otSDKStub.js" data-language="en" type="text/javascript" charset="UTF-8" data-domain-script="cc9e01f9-42aa-45f2-8fd9-6aad57d2a454" ></script>\r\n <script type="text/javascript">\r\n function OptanonWrapper() { }\r\n </script>\r\n <!-- CookiePro Cookies Consent Notice end for sigthglassvision.com --> """ "cookies_settings" => """ <!-- CookiePro Cookies Settings button start -->\r\n <button id="ot-sdk-btn" class="ot-sdk-show-settings">Cookie Settings</button>\r\n <!-- CookiePro Cookies Settings button end --> """ "head_script" => """ <!-- OptanonConsentNoticeStart -->\r\n <script type="text/javascript" src="https://cookie-cdn.cookiepro.com/consent/744b26cb-86ab-4e89-a59b-cfbbf29ba084/OtAutoBlock.js" ></script>\r\n <script src="https://cookie-cdn.cookiepro.com/scripttemplates/otSDKStub.js" data-language="en" type="text/javascript" charset="UTF-8" data-domain-script="744b26cb-86ab-4e89-a59b-cfbbf29ba084" ></script>\r\n <script type="text/javascript">\r\n function OptanonWrapper() { }\r\n </script>\r\n <!-- OptanonConsentNoticeEnd -->\r\n \r\n <!-- Matomo Tag Manager -->\r\n <script>\r\n var _mtm = window._mtm = window._mtm || [];\r\n _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'});\r\n (function() {\r\n var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];\r\n g.async=true; g.src='https://cdn.matomo.cloud/sightglassvision.matomo.cloud/container_1jgHGOOS.js'; s.parentNode.insertBefore(g,s);\r\n })();\r\n </script>\r\n <!-- End Matomo Tag Manager -->\r\n \r\n <meta name="google-site-verification" content="v_cGrVKdNBBPXpkyiV-7SIsER2l1nXqiwNUL3oWx6hM" /> """ "social_linkedin" => "https://www.linkedin.com/company/sightglassvision" "social_twitter" => "" "social_youtube" => "" ] "is_device" => false "links" => array:1 [ "archives" => array:1 [ "news" => "https://sgv.disko.love/blog/" ] ] "clear_head_for_yoast" => true "google_map_api_key" => "AIzaSyDGF98psyVSiyiVhFovqfhMDrGJ-Ls2Uoc" "blog_page_url" => "https://sgv.disko.love/blog/" "homeUrl" => "https://sgv.disko.love" "translations" => array:10 [ "yagami_demo_title" => "Site de démonstration<br/> du starter thème Yagami Adveris\n" "yagami_demo_content" => "Ce site Wordpress de démonstration présente le starter Adveris avec le thème "Yagami Adveris". Ce starter installe nativement les modules clés pour un site Wordpress optimisé. Le thème est ensuite adapté au design 100% sur-mesure créé par le studio créatif de l'agence.\n" "error_404_message" => "Cette page n'existe pas\n" "back_to_home" => "Retour à l'accueil\n" "news" => "Article\n" "all_news" => "All articles" "others_news" => "Other articles" "published_on" => "Published on" "play_video" => "Play video" "press_release" => "Press Release" ] "http_host" => "https://sgv.disko.love" "wp_title" => "SightGlass Vision | Press Release" "body_class" => "page-template page-template-press page page-id-419" "site" => Timber\Site {#2863 +id: null +ID: null +object_type: null +admin_email: "tech@disko.fr" +blogname: null +charset: "UTF-8" +description: "" +language: "en_US" +multisite: false +name: "SightGlass Vision" +pingback_url: "https://sgv.disko.love/xmlrpc.php" +siteurl: null +theme: Timber\Theme {#2868 +id: null +ID: null +object_type: null +name: "Yagami - Adveris" +version: "" +parent: false +parent_slug: null +slug: "yagami-adveris" +uri: "https://sgv.disko.love/wp-content/themes/yagami-adveris" -theme: WP_Theme {#2869 +update: false -theme_root: "/opt/bitnami/wordpress/wp-content/themes" -headers: array:14 [ "Name" => "Yagami - Adveris" "ThemeURI" => "" "Description" => "Custom starter to build wordpress theme from scratch" "Author" => "Adveris" "AuthorURI" => "https://www.adveris.fr/" "Version" => "" "Template" => "" "Status" => "" "Tags" => "yagami, blank" "TextDomain" => "Yagami" "DomainPath" => "" "RequiresWP" => "" "RequiresPHP" => "" "UpdateURI" => "" ] -headers_sanitized: array:2 [ "Name" => "Yagami - Adveris" "Version" => "" ] -block_theme: false -name_translated: null -errors: null -stylesheet: "yagami-adveris" -template: "yagami-adveris" -parent: null -theme_root_uri: "https://sgv.disko.love/wp-content/themes" -textdomain_loaded: null -cache_hash: "a5902282552af3f00ade54f56095ec22" -block_template_folders: array:2 [ "wp_template" => "templates" "wp_template_part" => "parts" ] -default_template_folders: array:2 [ "wp_template" => "templates" "wp_template_part" => "parts" ] } } +title: "SightGlass Vision" +url: "https://sgv.disko.love" +home_url: "https://sgv.disko.love" +site_url: "https://sgv.disko.love" +rdf: "https://sgv.disko.love/feed/rdf/" +rss: "https://sgv.disko.love/feed/rss/" +rss2: "https://sgv.disko.love/feed/" +atom: "https://sgv.disko.love/feed/atom/" +"pingback": "https://sgv.disko.love/xmlrpc.php" } "request" => Timber\Request {#2854 +id: null +ID: null +object_type: null +post: [] +get: [] } "user" => false "theme" => Timber\Theme {#2868} "posts" => Timber\PostQuery {#2870 +found_posts: 1 : 1 #userQuery: false #queryIterator: Timber\QueryIterator {#2871 -_query: WP_Query {#1108 +query: array:2 [ "page" => "" "pagename" => "press-release" ] +query_vars: array:66 [ "page" => 0 "pagename" => "press-release" "error" => "" "m" => "" "p" => 0 "post_parent" => "" "subpost" => "" "subpost_id" => "" "attachment" => "" "attachment_id" => 0 "name" => "press-release" "page_id" => 0 "second" => "" "minute" => "" "hour" => "" "day" => 0 "monthnum" => 0 "year" => 0 "w" => 0 "category_name" => "" "tag" => "" "cat" => "" "tag_id" => "" "author" => "" "author_name" => "" "feed" => "" "tb" => "" "paged" => 0 "meta_key" => "" "meta_value" => "" "preview" => "" "s" => "" "sentence" => "" "title" => "" "fields" => "" "menu_order" => "" "embed" => "" "category__in" => [] "category__not_in" => [] "category__and" => [] "post__in" => [] "post__not_in" => [] "post_name__in" => [] "tag__in" => [] "tag__not_in" => [] "tag__and" => [] "tag_slug__in" => [] "tag_slug__and" => [] "post_parent__in" => [] "post_parent__not_in" => [] "author__in" => [] "author__not_in" => [] "search_columns" => [] "ignore_sticky_posts" => false "suppress_filters" => false "cache_results" => true "update_post_term_cache" => true "update_menu_item_cache" => false "lazy_load_term_meta" => true "update_post_meta_cache" => true "post_type" => "" "posts_per_page" => 10 "nopaging" => false "comments_per_page" => "50" "no_found_rows" => false "order" => "DESC" ] +tax_query: null +meta_query: WP_Meta_Query {#2539 +queries: [] +relation: null +meta_table: null +meta_id_column: null +primary_table: null +primary_id_column: null #table_aliases: [] #clauses: [] #has_or_relation: false } +date_query: false +queried_object: WP_Post {#2536 +ID: 419 +post_author: "1" +post_date: "2023-05-03 11:09:45" +post_date_gmt: "2023-05-03 09:09:45" +post_content: "" +post_title: "Press Release" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "press-release" +to_ping: "" +pinged: "" +post_modified: "2023-06-27 16:52:08" +post_modified_gmt: "2023-06-27 14:52:08" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?page_id=419" +menu_order: 0 +post_type: "page" +post_mime_type: "" +comment_count: "0" +filter: "raw" } +queried_object_id: 419 +request: """ SELECT wp_posts.*\n \t\t\t\t\t FROM wp_posts \n \t\t\t\t\t WHERE 1=1 AND (wp_posts.ID = '419') AND wp_posts.post_type = 'page'\n \t\t\t\t\t \n \t\t\t\t\t ORDER BY wp_posts.post_date DESC\n \t\t\t\t\t """ +posts: & array:1 [ 0 => WP_Post {#2540 +ID: 419 +post_author: "1" +post_date: "2023-05-03 11:09:45" +post_date_gmt: "2023-05-03 09:09:45" +post_content: "" +post_title: "Press Release" +post_excerpt: "" +post_status: "publish" +comment_status: "closed" +ping_status: "closed" +post_password: "" +post_name: "press-release" +to_ping: "" +pinged: "" +post_modified: "2023-06-27 16:52:08" +post_modified_gmt: "2023-06-27 14:52:08" +post_content_filtered: "" +post_parent: 0 +guid: "https://www.sightglassvision.com/?page_id=419" +menu_order: 0 +post_type: "page" +post_mime_type: "" +comment_count: "0" +filter: "raw" +"status": "publish" +"id": 419 +"slug": "press-release" +"custom": array:11 [ "_edit_last" => "1" "_wp_page_template" => "press" "_yoast_wpseo_estimated-reading-time-minutes" => "0" "_yoast_wpseo_wordproof_timestamp" => "" "references" => "" "_references" => "field_644943738e91a" "_edit_lock" => "1692709771:4" "featured_pages" => array:1 [ …1] "_featured_pages" => "field_64522e2a4e468" "_yoast_wpseo_title" => "%%sitename%% %%sep%% %%title%%" "_yoast_wpseo_metadesc" => "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." ] } ] +post_count: 1 +current_post: -1 +before_loop: true +in_the_loop: false +post: WP_Post {#2540} +comment_count: 0 +current_comment: -1 +found_posts: 1 +max_num_pages: 0 +max_num_comment_pages: 0 +is_single: false +is_preview: false +is_page: true +is_archive: false +is_date: false +is_year: false +is_month: false +is_day: false +is_time: false +is_author: false +is_category: false +is_tag: false +is_tax: false +is_search: false +is_feed: false +is_comment_feed: false +is_trackback: false +is_home: false +is_privacy_policy: false +is_404: false +is_embed: false +is_paged: false +is_admin: false +is_attachment: false +is_singular: true +is_robots: false +is_favicon: false +is_posts_page: false +is_post_type_archive: false -query_vars_hash: "8b3e11791d3e223569b8f01969a5cc07" -query_vars_changed: false +thumbnails_cached: false #allow_query_attachment_by_filename: false -stopwords: null -compat_fields: array:2 [ 0 => "query_vars_hash" 1 => "query_vars_changed" ] -compat_methods: array:2 [ 0 => "init_query_flags" 1 => "parse_tax_query" ] } -_posts_class: "\Timber\Post" } #pagination: null -storage: array:1 [ 0 => Timber\Post {#2873 +id: 419 +ID: 419 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:11 [ "_edit_last" => "1" "_wp_page_template" => "press" "_yoast_wpseo_estimated-reading-time-minutes" => "0" "_yoast_wpseo_wordproof_timestamp" => "" "references" => "" "_references" => "field_644943738e91a" "_edit_lock" => "1692709771:4" "featured_pages" => array:1 [ 0 => "432" ] "_featured_pages" => "field_64522e2a4e468" "_yoast_wpseo_title" => "%%sitename%% %%sep%% %%title%%" "_yoast_wpseo_metadesc" => "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." ] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: "" +post_date: "2023-05-03 11:09:45" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "Press Release" +post_type: "page" +slug: "press-release" #__type: null +"_edit_last": "1" +"_wp_page_template": "press" +"_yoast_wpseo_estimated-reading-time-minutes": "0" +"_yoast_wpseo_wordproof_timestamp": "" +"references": "" +"_references": "field_644943738e91a" +"_edit_lock": "1692709771:4" +"featured_pages": array:1 [ 0 => "432" ] +"_featured_pages": "field_64522e2a4e468" +"_yoast_wpseo_title": "%%sitename%% %%sep%% %%title%%" +"_yoast_wpseo_metadesc": "Stay informed on SightGlass Vision's latest innovations, industry developments and company announcements with our press releases." +"post_date_gmt": "2023-05-03 09:09:45" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "press-release" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-27 16:52:08" +"post_modified_gmt": "2023-06-27 14:52:08" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?page_id=419" +"menu_order": 0 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"status": "publish" } ] : false : false : "Timber\PostsIterator" } "wp_head" => Timber\FunctionWrapper {#2872 -_class: null -_function: "wp_head" -_args: [] -_use_ob: false } "wp_footer" => Timber\FunctionWrapper {#2875 -_class: null -_function: "wp_footer" -_args: [] -_use_ob: false } "menu" => array:3 [ "primary" => Timber\Menu {#2877 +id: 7 +ID: 7 +object_type: "term" +PostClass: "Timber\Post" +TermClass: "Term" +_children: null +name: "Header" +taxonomy: "nav_menu" +MenuItemClass: "Timber\MenuItem" +depth: 0 +items: array:5 [ 0 => Timber\MenuItem {#2883 +id: 517 +ID: 517 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-517" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-517" +level: 0 +post_name: "517" +url: "https://sgv.disko.love/diffusion-optics-technology/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2877} #_name: null #_menu_item_object_id: "182" #_menu_item_url: "" #menu_object: Timber\Post {#2881 +id: 517 +ID: 517 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:20:26" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "517" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "182" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:4 [ …4] +"post_date_gmt": "2023-05-10 14:55:37" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "517" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=517" +"menu_order": 1 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 517 +"menu_item_parent": "0" +"object_id": "182" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/diffusion-optics-technology/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Diffusion Optics Technology™" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "182" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:4 [ …4] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:20:26" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:4 [ 0 => "2023-05-10" 1 => "2023-05-17" 2 => "2023-05-22" 3 => "2023-05-23" ] +"post_date_gmt": "2023-05-10 14:55:37" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=517" +"menu_order": 1 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 517 +"menu_item_parent": "0" +"object_id": "182" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Diffusion Optics Technology™" +"status": "publish" +"name": "Diffusion Optics Technology™" } 1 => Timber\MenuItem {#2884 +id: 641 +ID: 641 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-641" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-641" +level: 0 +post_name: "641" +url: "https://sgv.disko.love/all-about-myopia/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2877} #_name: null #_menu_item_object_id: "591" #_menu_item_url: "" #menu_object: Timber\Post {#2786 +id: 641 +ID: 641 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:20:26" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "641" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "591" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": "2023-05-23" +"post_date_gmt": "2023-05-23 07:59:49" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "641" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=641" +"menu_order": 2 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 641 +"menu_item_parent": "0" +"object_id": "591" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/all-about-myopia/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "All about Myopia" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "591" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => "2023-05-23" ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:20:26" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": "2023-05-23" +"post_date_gmt": "2023-05-23 07:59:49" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=641" +"menu_order": 2 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 641 +"menu_item_parent": "0" +"object_id": "591" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "All about Myopia" +"status": "publish" +"name": "All about Myopia" } 2 => Timber\MenuItem {#2784 +id: 740 +ID: 740 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-740" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-740" +level: 0 +post_name: "740" +url: "https://sgv.disko.love/about-us/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2877} #_name: null #_menu_item_object_id: "721" #_menu_item_url: "" #menu_object: Timber\Post {#2785 +id: 740 +ID: 740 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:8 [ …8] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:20:26" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "740" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "721" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"post_date_gmt": "2023-06-02 13:20:26" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "740" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=740" +"menu_order": 3 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 740 +"menu_item_parent": "0" +"object_id": "721" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/about-us/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "About Us" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:8 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "721" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:20:26" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"post_date_gmt": "2023-06-02 13:20:26" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=740" +"menu_order": 3 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 740 +"menu_item_parent": "0" +"object_id": "721" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "About Us" +"status": "publish" +"name": "About Us" } 3 => Timber\MenuItem {#3174 +id: 555 +ID: 555 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-555" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-555" +level: 0 +post_name: "555" +url: "https://sgv.disko.love/blog/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2877} #_name: null #_menu_item_object_id: "339" #_menu_item_url: "" #menu_object: Timber\Post {#2783 +id: 555 +ID: 555 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:20:26" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "555" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "339" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:3 [ …3] +"post_date_gmt": "2023-05-17 07:30:30" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "555" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=555" +"menu_order": 4 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 555 +"menu_item_parent": "0" +"object_id": "339" +"object": "page" +"type_label": "Posts Page" +"url": "https://sgv.disko.love/blog/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Blog" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "339" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:3 [ …3] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:20:26" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:3 [ 0 => "2023-05-17" 1 => "2023-05-22" 2 => "2023-05-23" ] +"post_date_gmt": "2023-05-17 07:30:30" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:26" +"post_modified_gmt": "2023-06-02 13:20:26" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=555" +"menu_order": 4 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 555 +"menu_item_parent": "0" +"object_id": "339" +"object": "page" +"type_label": "Posts Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Blog" +"status": "publish" +"name": "Blog" } 4 => Timber\MenuItem {#3176 +id: 518 +ID: 518 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-518" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-518" +level: 0 +post_name: "518" +url: "https://sgv.disko.love/where-to-find/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2877} #_name: null #_menu_item_object_id: "160" #_menu_item_url: "" #menu_object: Timber\Post {#3175 +id: 518 +ID: 518 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:20:27" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "518" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "160" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:4 [ …4] +"post_date_gmt": "2023-05-10 14:55:37" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "518" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:27" +"post_modified_gmt": "2023-06-02 13:20:27" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=518" +"menu_order": 5 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 518 +"menu_item_parent": "0" +"object_id": "160" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/where-to-find/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Where to find" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "160" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:4 [ …4] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:20:27" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:4 [ 0 => "2023-05-10" 1 => "2023-05-17" 2 => "2023-05-22" 3 => "2023-05-23" ] +"post_date_gmt": "2023-05-10 14:55:37" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:20:27" +"post_modified_gmt": "2023-06-02 13:20:27" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=518" +"menu_order": 5 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 518 +"menu_item_parent": "0" +"object_id": "160" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Where to find" +"status": "publish" +"name": "Where to find" } ] +term_id: 7 +title: "Header" +options: array:1 [ "depth" => 0 ] +raw_options: [] +theme_location: "primary" +"slug": "header" +"term_group": 0 +"term_taxonomy_id": 7 +"parent": 0 +"count": 5 +"filter": "raw" } "secondary" => Timber\Menu {#2841 +id: 3 +ID: 3 +object_type: "term" +PostClass: "Timber\Post" +TermClass: "Term" +_children: null +name: "Footer" +taxonomy: "nav_menu" +MenuItemClass: "Timber\MenuItem" +depth: 0 +items: array:7 [ 0 => Timber\MenuItem {#3168 +id: 428 +ID: 428 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-428" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-428" +level: 0 +post_name: "428" +url: "https://sgv.disko.love/diffusion-optics-technology/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2841} #_name: null #_menu_item_object_id: "182" #_menu_item_url: "" #menu_object: Timber\Post {#3170 +id: 428 +ID: 428 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:22:09" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "428" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "182" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:2 [ …2] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "428" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=428" +"menu_order": 1 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 428 +"menu_item_parent": "0" +"object_id": "182" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/diffusion-optics-technology/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Diffusion Optics Technology™" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "182" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:2 [ …2] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:22:09" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:2 [ 0 => "2023-05-03" 1 => "2023-05-10" ] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=428" +"menu_order": 1 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 428 +"menu_item_parent": "0" +"object_id": "182" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Diffusion Optics Technology™" +"status": "publish" +"name": "Diffusion Optics Technology™" } 1 => Timber\MenuItem {#3167 +id: 434 +ID: 434 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-434" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-434" +level: 0 +post_name: "434" +url: "https://sgv.disko.love/careers/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2841} #_name: null #_menu_item_object_id: "432" #_menu_item_url: "" #menu_object: Timber\Post {#3082 +id: 434 +ID: 434 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: "" +post_date: "2023-06-02 15:22:09" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "Careers" +post_type: "nav_menu_item" +slug: "434" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "432" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:2 [ …2] +"post_date_gmt": "2023-05-03 12:27:48" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "434" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=434" +"menu_order": 2 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 434 +"menu_item_parent": "0" +"object_id": "432" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/careers/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Careers" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "432" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:2 [ …2] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": "" +"post_date": "2023-06-02 15:22:09" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "Careers" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:2 [ 0 => "2023-05-03" 1 => "2023-05-10" ] +"post_date_gmt": "2023-05-03 12:27:48" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=434" +"menu_order": 2 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 434 +"menu_item_parent": "0" +"object_id": "432" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Careers" +"status": "publish" +"name": "Careers" } 2 => Timber\MenuItem {#3080 +id: 429 +ID: 429 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-429" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-429" +level: 0 +post_name: "429" +url: "https://sgv.disko.love/resources-for-eye-care-professionals/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2841} #_name: null #_menu_item_object_id: "424" #_menu_item_url: "" #menu_object: Timber\Post {#3081 +id: 429 +ID: 429 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:22:09" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "429" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "424" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:2 [ …2] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "429" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=429" +"menu_order": 3 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 429 +"menu_item_parent": "0" +"object_id": "424" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/resources-for-eye-care-professionals/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Resources for Eye Care Professionals" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "424" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:2 [ …2] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:22:09" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:2 [ 0 => "2023-05-03" 1 => "2023-05-10" ] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=429" +"menu_order": 3 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 429 +"menu_item_parent": "0" +"object_id": "424" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Resources for Eye Care Professionals" +"status": "publish" +"name": "Resources for Eye Care Professionals" } 3 => Timber\MenuItem {#2639 +id: 431 +ID: 431 +object_type: "post" +children: [] +has_child_class: false +classes: array:9 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "current-menu-item" 5 => "page_item" 6 => "page-item-419" 7 => "current_page_item" 8 => "menu-item-431" ] +class: "menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-419 current_page_item menu-item-431" +level: 0 +post_name: "431" +url: "https://sgv.disko.love/press-release/" +PostClass: "Timber\Post" +current: true +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2841} #_name: null #_menu_item_object_id: "419" #_menu_item_url: "" #menu_object: Timber\Post {#2638 +id: 431 +ID: 431 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:22:09" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "431" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "419" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:2 [ …2] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "431" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=431" +"menu_order": 4 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 431 +"menu_item_parent": "0" +"object_id": "419" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/press-release/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:8 [ …8] +"xfn": "" +"current": true +"current_item_ancestor": false +"current_item_parent": false +"__title": "Press Release" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "419" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:2 [ …2] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:22:09" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:2 [ 0 => "2023-05-03" 1 => "2023-05-10" ] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=431" +"menu_order": 4 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 431 +"menu_item_parent": "0" +"object_id": "419" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Press Release" +"status": "publish" +"name": "Press Release" } 4 => Timber\MenuItem {#2641 +id: 440 +ID: 440 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-440" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-440" +level: 0 +post_name: "440" +url: "https://sgv.disko.love/resources-for-parents/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2841} #_name: null #_menu_item_object_id: "435" #_menu_item_url: "" #menu_object: Timber\Post {#2640 +id: 440 +ID: 440 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:22:09" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "440" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "435" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:2 [ …2] +"post_date_gmt": "2023-05-03 12:29:00" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "440" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=440" +"menu_order": 5 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 440 +"menu_item_parent": "0" +"object_id": "435" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/resources-for-parents/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Resources for Parents" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "435" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:2 [ …2] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:22:09" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:2 [ 0 => "2023-05-03" 1 => "2023-05-10" ] +"post_date_gmt": "2023-05-03 12:29:00" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=440" +"menu_order": 5 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 440 +"menu_item_parent": "0" +"object_id": "435" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Resources for Parents" +"status": "publish" +"name": "Resources for Parents" } 5 => Timber\MenuItem {#2643 +id: 430 +ID: 430 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-430" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-430" +level: 0 +post_name: "430" +url: "https://sgv.disko.love/blog/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2841} #_name: null #_menu_item_object_id: "339" #_menu_item_url: "" #menu_object: Timber\Post {#2642 +id: 430 +ID: 430 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:9 [ …9] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:22:09" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "430" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "339" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"_wp_old_date": array:2 [ …2] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "430" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=430" +"menu_order": 6 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 430 +"menu_item_parent": "0" +"object_id": "339" +"object": "page" +"type_label": "Posts Page" +"url": "https://sgv.disko.love/blog/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "Blog" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "339" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" "_wp_old_date" => array:2 [ …2] ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:22:09" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"_wp_old_date": array:2 [ 0 => "2023-05-03" 1 => "2023-05-10" ] +"post_date_gmt": "2023-05-03 12:27:07" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=430" +"menu_order": 6 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 430 +"menu_item_parent": "0" +"object_id": "339" +"object": "page" +"type_label": "Posts Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Blog" +"status": "publish" +"name": "Blog" } 6 => Timber\MenuItem {#2645 +id: 741 +ID: 741 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-741" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-741" +level: 0 +post_name: "741" +url: "https://sgv.disko.love/about-us/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#2841} #_name: null #_menu_item_object_id: "721" #_menu_item_url: "" #menu_object: Timber\Post {#2644 +id: 741 +ID: 741 +object_type: "post" +ImageClass: "Timber\Image" +PostClass: "Timber\Post" +TermClass: "Timber\Term" +custom: array:8 [ …8] #___content: null #_permalink: null #_next: [] #_prev: [] #_css_class: null +post_author: "1" +post_content: " " +post_date: "2023-06-02 15:22:09" +post_excerpt: "" +post_parent: 0 +post_status: "publish" +post_title: "" +post_type: "nav_menu_item" +slug: "741" #__type: null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object_id": "721" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_menu_item_url": "" +"post_date_gmt": "2023-06-02 13:21:37" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"post_name": "741" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=741" +"menu_order": 7 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 741 +"menu_item_parent": "0" +"object_id": "721" +"object": "page" +"type_label": "Page" +"url": "https://sgv.disko.love/about-us/" +"target": "" +"attr_title": "" +"description": "" +"classes": array:4 [ …4] +"xfn": "" +"current": false +"current_item_ancestor": false +"current_item_parent": false +"__title": "About Us" +"status": "publish" } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:8 [ "_menu_item_type" => "post_type" "_menu_item_menu_item_parent" => "0" "_menu_item_object_id" => "721" "_menu_item_object" => "page" "_menu_item_target" => "" "_menu_item_classes" => array:1 [ …1] "_menu_item_xfn" => "" "_menu_item_url" => "" ] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-02 15:22:09" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ 0 => "" ] +"_menu_item_xfn": "" +"post_date_gmt": "2023-06-02 13:21:37" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-02 15:22:09" +"post_modified_gmt": "2023-06-02 13:22:09" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=741" +"menu_order": 7 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 741 +"menu_item_parent": "0" +"object_id": "721" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "About Us" +"status": "publish" +"name": "About Us" } ] +term_id: 3 +title: "Footer" +options: array:1 [ "depth" => 0 ] +raw_options: [] +theme_location: "secondary" +"slug": "footer" +"term_group": 0 +"term_taxonomy_id": 3 +"parent": 0 +"count": 7 +"filter": "raw" } "links" => Timber\Menu {#3156 +id: 2 +ID: 2 +object_type: "term" +PostClass: "Timber\Post" +TermClass: "Term" +_children: null +name: "Footer - Liens" +taxonomy: "nav_menu" +MenuItemClass: "Timber\MenuItem" +depth: 0 +items: array:3 [ 0 => Timber\MenuItem {#2632 +id: 174 +ID: 174 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ 0 => "" 1 => "menu-item" 2 => "menu-item-type-post_type" 3 => "menu-item-object-page" 4 => "menu-item-174" ] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-174" +level: 0 +post_name: "174" +url: "https://sgv.disko.love/terms-and-conditions/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#3156} #_name: null #_menu_item_object_id: "6" #_menu_item_url: "" #menu_object: Timber\Post {#2634 +id: 174 +ID: 174 +object_type: "post" …59 } +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ …9] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-26 15:41:44" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_wp_old_date": "2023-04-12" +"post_date_gmt": "2023-04-12 14:21:55" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-26 15:41:44" +"post_modified_gmt": "2023-06-26 13:41:44" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=174" +"menu_order": 1 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 174 +"menu_item_parent": "0" +"object_id": "6" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Terms and conditions" +"status": "publish" +"name": "Terms and conditions" } 1 => Timber\MenuItem {#2599 +id: 173 +ID: 173 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ …5] +class: "menu-item menu-item-type-post_type menu-item-object-page menu-item-173" +level: 0 +post_name: "173" +url: "https://sgv.disko.love/data-privacy-policy/" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#3156} #_name: null #_menu_item_object_id: "3" #_menu_item_url: "" #menu_object: Timber\Post {#2631 …62} +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:9 [ …9] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": " " +"post_date": "2023-06-26 15:41:44" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "post_type" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "page" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"_wp_old_date": "2023-04-12" +"post_date_gmt": "2023-04-12 14:21:56" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-26 15:41:44" +"post_modified_gmt": "2023-06-26 13:41:44" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=173" +"menu_order": 2 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 173 +"menu_item_parent": "0" +"object_id": "3" +"object": "page" +"type_label": "Page" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Data Privacy Policy" +"status": "publish" +"name": "Data Privacy Policy" } 2 => Timber\MenuItem {#2620 +id: 1028 +ID: 1028 +object_type: "post" +children: [] +has_child_class: false +classes: array:5 [ …5] +class: "ot-sdk-show-settings menu-item menu-item-type-custom menu-item-object-custom menu-item-1028" +level: 0 +post_name: "cookie-settings" +url: "#cookie-settings" +PostClass: "Timber\Post" +current: false +current_item_parent: false +current_item_ancestor: false #menu: Timber\Menu {#3156} #_name: null #_menu_item_object_id: "1028" #_menu_item_url: "#cookie-settings" #menu_object: Timber\Post {#2598 …61} +"ImageClass": "Timber\Image" +"TermClass": "Timber\Term" +"custom": array:8 [ …8] +"___content": null +"_permalink": null +"_next": [] +"_prev": [] +"_css_class": null +"post_author": "1" +"post_content": "" +"post_date": "2023-06-26 15:41:44" +"post_excerpt": "" +"post_parent": 0 +"post_status": "publish" +"post_title": "Cookie Settings" +"post_type": "nav_menu_item" +"__type": null +"_menu_item_type": "custom" +"_menu_item_menu_item_parent": "0" +"_menu_item_object": "custom" +"_menu_item_target": "" +"_menu_item_classes": array:1 [ …1] +"_menu_item_xfn": "" +"post_date_gmt": "2023-06-26 13:37:10" +"comment_status": "closed" +"ping_status": "closed" +"post_password": "" +"to_ping": "" +"pinged": "" +"post_modified": "2023-06-26 15:41:45" +"post_modified_gmt": "2023-06-26 13:41:45" +"post_content_filtered": "" +"guid": "https://www.sightglassvision.com/?p=1028" +"menu_order": 3 +"post_mime_type": "" +"comment_count": "0" +"filter": "raw" +"db_id": 1028 +"menu_item_parent": "0" +"object_id": "1028" +"object": "custom" +"type_label": "Custom Link" +"target": "" +"attr_title": "" +"description": "" +"xfn": "" +"__title": "Cookie Settings" +"status": "publish" +"name": "Cookie Settings" } ] +term_id: 2 +title: "Footer - Liens" +options: array:1 [ "depth" => 0 ] +raw_options: [] +theme_location: "links" +"slug": "footer-liens" +"term_group": 0 +"term_taxonomy_id": 2 +"parent": 0 +"count": 3 +"filter": "raw" } ] ]
Super Globals
$_COOKIE
^ []
$_SERVER
^ array:39 [ "SERVER_SOFTWARE" => "Apache" "REQUEST_URI" => "/press-release/" "PATH" => "/opt/bitnami/apache/bin:/opt/bitnami/common/bin:/opt/bitnami/apache/bin:/opt/bitnami/apache2/bin:/opt/bitnami/brotli/bin:/opt/bitnami/common/bin:/opt/bitnami/gonit/bin:/opt/bitnami/mariadb/bin:/opt/bitnami/mariadb/sbin:/opt/bitnami/mysql/bin:/opt/bitnami/php/bin:/opt/bitnami/php/sbin:/opt/bitnami/varnish/bin:/opt/bitnami/varnish/sbin:/opt/bitnami/wp-cli/bin:/opt/bitnami/nami/bin:/opt/bitnami/apache/bin:/opt/bitnami/apache2/bin:/opt/bitnami/brotli/bin:/opt/bitnami/common/bin:/opt/bitnami/gonit/bin:/opt/bitnami/mariadb/bin:/opt/bitnami/mariadb/sbin:/opt/bitnami/mysql/bin:/opt/bitnami/php/bin:/opt/bitnami/php/sbin:/opt/bitnami/varnish/bin:/opt/bitnami/varnish/sbin:/opt/bitnami/wp-cli/bin:/opt/bitnami/nami/bin:/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin" "USER" => "daemon" "HOME" => "/usr/sbin" "SCRIPT_NAME" => "/index.php" "QUERY_STRING" => "" "REQUEST_METHOD" => "GET" "SERVER_PROTOCOL" => "HTTP/1.1" "GATEWAY_INTERFACE" => "CGI/1.1" "REDIRECT_URL" => "/press-release/" "REMOTE_PORT" => "21893" "SCRIPT_FILENAME" => "/opt/bitnami/wordpress/index.php" "SERVER_ADMIN" => "you@example.com" "CONTEXT_DOCUMENT_ROOT" => "/opt/bitnami/wordpress" "CONTEXT_PREFIX" => "" "REQUEST_SCHEME" => "https" "DOCUMENT_ROOT" => "/opt/bitnami/wordpress" "REMOTE_ADDR" => "216.73.216.15" "SERVER_PORT" => "443" "SERVER_ADDR" => "172.31.33.40" "SERVER_NAME" => "sgv.disko.love" "SERVER_SIGNATURE" => "" "HTTP_HOST" => "sgv.disko.love" "HTTP_REFERER" => "https://sgv.disko.love/press-release" "HTTP_ACCEPT_ENCODING" => "gzip, br, zstd, deflate" "HTTP_USER_AGENT" => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)" "HTTP_ACCEPT" => "*/*" "SSL_TLS_SNI" => "sgv.disko.love" "HTTPS" => "on" "HTTP_AUTHORIZATION" => "" "REDIRECT_STATUS" => "200" "REDIRECT_SSL_TLS_SNI" => "sgv.disko.love" "REDIRECT_HTTPS" => "on" "REDIRECT_HTTP_AUTHORIZATION" => "" "FCGI_ROLE" => "RESPONDER" "PHP_SELF" => "/index.php" "REQUEST_TIME_FLOAT" => 1773829897.9881 "REQUEST_TIME" => 1773829897 ]
User
^ false